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Autoantibodies are frequently observed in healthy individuals. In a minority of these 
individuals, they lead to manifestation of autoimmune diseases, such as rheumatoid 
arthritis or Graves’ disease. Overall, more than 2.5% of the population is affected by 
autoantibody-driven autoimmune disease. Pathways leading to autoantibody-induced 
pathology greatly differ among different diseases, and autoantibodies directed against 
the same antigen, depending on the targeted epitope, can have diverse effects. To 
foster knowledge in autoantibody-induced pathology and to encourage development 
of urgently needed novel therapeutic strategies, we here categorized autoantibodies 
according to their effects. According to our algorithm, autoantibodies can be classified 
into the following categories: (1) mimic receptor stimulation, (2) blocking of neural trans-
mission, (3) induction of altered signaling, triggering uncontrolled (4) microthrombosis, (5) 
cell lysis, (6) neutrophil activation, and (7) induction of inflammation. These mechanisms 
in relation to disease, as well as principles of autoantibody generation and detection, are 
reviewed herein.
Keywords: autoimmunity, autoantibodies, treatment, pathogenesis, mouse models, B cells, diagnosis
TABLE 1 | Autoantibody-mediated diseases not discussed in this review.
Disease Autoantibody(ies) Pathogenic mechanism Reference
Systemic lupus 
erythematosus (SLE)
Several, for example, ANA, anti-dsDNA – Transfer of human SLE serum induces nephritis in mice
– Depends on Mac-1 regulation of FcγRIIA-mediated neutrophil recruitment
(5)
Sjögren’s syndrome Several, for example anti-Ro, anti-La, ANA Immunization with Ro leads to a decrease in salivary flow and lymphocytic  
infiltration in the salivary glands
(6, 7)
Autoimmune myopathies Several, anti-SRP, anti-HMGCR, anti-myosin Immunization with muscle homogenisates induces autoantibodies and myositis  
in SJL/J mice
(8, 9)
Type I diabetes Several, directed against insulin, glutamic 
acid decarboxylase and protein tyrosine 
phosphatase
Autoantibodies are associated with insulits and/or onset of diabetes (10, 11)
Addison disease Anti-steroidogenic cytochrome P450 enzyme 
21-hydroxylase
– Present in patients
– Induction of immune responses upon immunization in mice
(12)
Pernicious anemia Anti-parietal cell antibodies Reduced uptake of vitamin B12 due to lack of intrinsic factor (13)
Autoimmune hepatitis Several, anti-ASMA, anti-actin, ANA – Used for diagnosis
– Detection of autoantibodies in mouse models of the disease
(14)
Primary biliary cholangitis 
(PBC)
Antimitochondrial antibodies – Used for diagnosis
– Observed in mice with PBC
(15, 16)
Autoimmune pancreatitis Anti-amylase α2 – Used for diagnosis
– Observed in mice with the disease
(17, 18)
Goodpasture’s disease Anti-type IV collagen antibodies (COL4) – Immunization with COL4 induces the disease in mice
– Production of autoantibodies T cell-dependent
(19)
Primary membranous 
nephropathy
Anti-PLA2R, anti-THSD7A Anti-THSD7A induce proteinuria, and initiate a histopathological pattern that  
is typical of the disease
(19, 20)
Ovarian insufficiency Anti-HSP90, anti-HSPA5 HSPA5 immunization induces ovarian insufficiency in mice (21)
Autoimmune orchitis Antisperm antibodies Correlation of autoantibody titers with disease in mice (22, 23)
Dry eye disease Severla, for example, anti-kallikrein 13 – Antibody transfer induces disease
– Depends on complement and Gr-1+ cells
(24)
Idiopathic interstitial 
pneumonias
Several Not known so far (25)
In addition to the autoantibody-induced diseases covered in depth, there are several other diseases where autoantibodies can be detected and where autoantibodies are very likely 
to be involved in driving pathology. In most of these diseases, however, the contribution of autoantibodies is augmentation of the pathology and/or the direct contribution of the 
autoantibodies is less clear than in the diseases covered herein.
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AUTOANTIBODY-MEDIATED DISEASES: 
ONE MAJOR MEDICAL BURDEN, A 
CONGREGATION OF DIFFERENT 
PATHWAYS TO DISEASE MANIFESTATION
Over the past decades, a sharp increase in autoimmune diseases 
has been noted worldwide (1, 2). The cumulative prevalence 
of autoimmune diseases caused by autoantibodies is well over 
2.5% (3). Despite developing insights into the pathogenesis of 
autoantibody-mediated autoimmune diseases (reviewed herein), 
systemic immunosuppression, i.e., with high doses of corticoster-
oids, is still the backbone of the treatment. Consequently, patients 
suffer from a high, and partially treatment-associated, morbidity 
and face an increased mortality (4). Thus, there is a high, and thus 
far, unmet medical need for development of novel treatments for 
patients suffering from autoantibody-mediated autoimmune 
diseases.
However, autoantibodies induce disease through a multitude 
of pathophysiological pathways. These differ among autoimmune 
diseases, yet within diseases multiple mechanisms may con-
tribute to clinical manifestation. To disentangle these different 
autoantibody-mediated disease mechanisms, we aimed to catego-
rize autoantibodies according to their main pathologic features. 
In brief, albeit surely not complete (Table  1), autoantibodies 
specific for a range of autoantigens induce pathology by a variety 
of mechanisms (Figure 1).
1. Mimic hormone stimulation of receptor: thyroid-stimulating 
autoantibodies (TSAb) in Graves’ disease.
2. Blockade of neural transmission by receptor blockade or 
alteration of the synaptic structures: antibodies against muscle 
nicotinic acetylcholine receptors (AChRs) in myasthenia 
gravis or against N-methyl-d-aspartate-(NMDA)-receptor in 
anti-NMDA encephalitis.
3. Induction of altered signaling: antibodies against desmoglein-3 
in pemphigus.
4. Triggering uncontrolled microthrombosis: autoantibodies 
against ADAMTS13 in acquired thrombotic thrombopenic 
purpura.
5. Cell lysis: anti-platelet autoantibodies in autoimmune idi-
opathic thrombocytopenia.
6. Uncontrolled neutrophil activation: antineutrophil cytoplas-
matic autoantibodies in granulomatosis with polyangitis.
FIGURE 1 | Multiple pathways lead to autoantibody-induced pathology. Depending on the targeted autoantigen, and sometimes even depending on the 
targeted epitope within a single autoantigen, autoantibodies induce pathology through specific and distinct mechanisms. Some are highlighted in this cartoon (from 
upper left to lower right): antibodies against the thyrotropin receptor (TSHR) mimic hormone stimulation of the TSHR receptor leading to hyperthyroidism, blockade 
of neural transmission by autoantibody binding to the corresponding receptors may lead to severe neurological diseases such as anti-N-methyl-D-aspartate 
encephalitis, autoantibody-mediated blockade of enzymes of the primary hemostasis may trigger uncontrolled microthrombosis, in pemphigus, autoantibodies 
induce an altered signaling in keratinocytes, which either reflects or leads to, a loss of cell–cell adhesion, resulting in severe skin blistering, autoantibodies to antigens 
expressed by neutrophils can lead to their uncontrolled activation, resulting in severe tissue injury, in autoimmune idiopathic thrombocytopenia autoantibodies trigger 
thrombocytopenia and severe bleeding, Fcγ-mediated functions may trigger tissue inflammation in many autoimmune diseases, e.g., rheumatoid arthritis and 
pemphigoid disease.
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7. Induction of inflammation at the site of autoantibody bind-
ing: autoantibodies against structural proteins of the skin in 
PD, or autoantibodies targeting myosin in myocarditis or 
autoantibodies recognizing citrullinated proteins in rheuma-
toid arthritis (RA) or autoantibodies targeting aquaporin-4 
(AQP4) in neuromyelitis optica (NMO).
With this review, we intend to foster knowledge in an increas-
ingly important medical field. Mostly, we encourage clinicians 
and scientists alike to build on the current knowledge on 
autoantibody-mediated pathology summarized here to develop 
urgently needed novel treatment modalities for patients suffering 
from autoantibody-mediated autoimmune diseases. We begin 
by briefly reviewing mechanisms leading to the generation and 
maintenance of autoantibodies, then discuss pathophysiological 
pathways in relation the corresponding diseases, and close by 
reviewing the diagnostic tools for autoantibody detection.
GENERATION AND MAINTENANCE  
OF AUTOANTIBODIES
The presence of autoantibodies in serum reflects leakiness 
of central and/or peripheral tolerance mechanisms, allowing 
the maturation of autoantibody-producing B  cells and their 
subsequent differentiation into antibody-secreting plasma cells. 
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The mechanisms that normally mediate B cell tolerance include 
multiple selection steps that deplete or functionally silence 
autoreactive B cells. These well-orchestrated processes occur at 
the B cell immature, transitional, and mature stages (26, 27), and 
possibly also after activation of B cells in the periphery before 
they enter the plasma cell compartment in bone marrow (28, 29). 
The complex mechanisms contributing to B  cell tolerance are 
multifaceted and may involve receptor editing, controlled migra-
tion, and limited availability of BAFF, CD22, Siglec-G, miRNA, 
and follicular regulatory T cells (30–36). These mechanisms have 
been extensively discussed elsewhere and are beyond the scope of 
this review. Nevertheless, we stress here that autoreactive B cells 
are selected against according to their receptor binding affinities 
(i.e., membrane-bound antibodies) to self-antigens. B cells pro-
ducing antibodies that bind with high affinity to self-antigens are 
efficiently eliminated or undergo anergy, while those B cells that 
produce autoantibodies with medium or low binding affinity may 
escape, even in non-autoimmune individuals (37, 38). Many of 
these low-affinity autoantibodies are polyreactive and recognize 
self-antigens as well as pathogen-derived antigens (38, 39).
Autoantibodies are not necessarily pathogenic. Natural poly-
reactive/autoreactive IgM antibodies can sometimes protect from 
autoimmune diseases (40). There is also increasing evidence that 
immunoglobulin (Ig)G autoantibodies can exhibit anti-inflam-
matory capacities, depending on their IgG subclass (isotype) and 
the extent of glycosylation/sialylation of the Fc glycan linked to 
Asn297 (41–43). These properties modulate antibody binding to 
a variety of different Fc-receptors on innate effector cells (43). 
This receptor family includes FcγRI (CD64), FcγRIIIA (CD16a), 
and FcγRIIIB (CD16b) that mediate activating signals, but also 
includes the inhibiting receptors FcγRIIA and FcγRIIB (CD32). 
Antibodies exhibiting a distinct glycosylation/sialylation status 
and/or belonging to different IgG subclasses bind to activating 
and inhibiting Fc-receptors with different affinities (41, 44). 
Consequently, IgG subclass and glycosylation/sialylation patterns 
determine whether an autoantibody exhibits FcγR-mediated 
pro-or anti-inflammatory functions (45). Hence, differential 
autoantibody glycosylation might be an important regulator of 
autoimmune disorders (46–48).
So far, little is known about the mechanisms that control 
antibody glycosylation/sialylation patterns. IgGs derived in the 
context of T-independent immune reactions in murine models 
were shown to exhibit a high degree of sialylation that mediates 
anti-inflammatory properties, while IgGs generated in the con-
text of T-dependent reactions were poorly sialylated and pro-
inflammatory. In mice deficient for both the IFN-γ and the IL-17 
receptors, T-dependent IgGs exhibit a high degree of sialylation, 
suggesting that T cell-derived IFN-γ and IL-17 are involved in 
the regulation of antibody sialylation (49). These experiments 
could not formally rule out the possibility that these cytokines 
were derived from cells other than T cells. Nevertheless, these 
observations suggest that similar to what is long known for 
antibody class switch (50), antibody sialylation is also modu-
lated by the interaction of activated B  cells with T follicular 
helper cells (49). Interestingly, both T cell differentiation into 
follicular helper T cells and cytokine profiles are modulated by 
activated B cells and plasma cells themselves, via presentation of 
antigen, co-stimulatory molecules, and B cell-derived cytokines 
(51–56). Following TLR stimulation, B cells produce different 
cytokines than dendritic cells (57). Dendritic cells might be the 
most important antigen-presenting cells during T  cell prim-
ing. However, there is evidence that later, antigen presentation 
by B cells is important to promote the expansion of activated 
T cell clones, the development of robust T effector responses, 
and normal T cell memory compartments (58–60). Moreover, 
it was shown that TLR-signals in murine B cells promote IFN-γ 
production from T cells and in consequence control antibody 
isotype switching to IgG2 in  vivo (57). Hence, the cross talk 
between activated B and T lymphocytes seems to be crucial for 
the outcome of antibody responses and their pathogenic poten-
tial, i.e., the antibody class and glycosylation pattern (Figure 2).
Measurement of autoantibodies is a major diagnostic tool in 
many diseases. However, autoantibodies are often found in oth-
erwise healthy individuals (61–64). Considering the importance 
of the autoantibody subclass and glycosylation pattern for the 
pathogenic potential of a particular antibody, it might be helpful 
to include these parameters into the diagnostic analysis.
Once the production of pathogenic autoantibodies has started, 
it could be maintained either by ongoing activation of autoreac-
tive B cells resulting in the continuous formation of short-lived 
plasma cells or through the formation of long-lived plasma cells, 
or both (65, 66). While B cell activation and short-lived plasma 
cell responses are suppressed by current therapeutic treatment 
options, long-lived plasma cells remain a therapeutic challenge 
(67, 68). A novel approach to deplete long-lived plasma cells and 
otherwise refractory autoantibodies is treatment with the pro-
teasome inhibitor bortezomib. This drug was shown to deplete 
short-lived and long-lived plasma cells in murine models of 
systemic lupus erythematosus (SLE) and experimental autoim-
mune myasthenia gravis. In these experiments, the capacity of 
bortezomib to suppress lupus nephritis and myasthenic symp-
toms has been demonstrated (69–71).
Results of the first clinical investigations using bortezomib 
for the treatment of refractory SLE and thrombotic thrombocy-
topenic purpura (TTP) are promising (72–74). However, addi-
tional controlled studies are required to elucidate the potential 
of bortezomib to eliminate otherwise refractory autoantibodies. 
Bortezomib affects neither naïve nor memory B  cells. Once 
long-lived plasma cells are depleted, these cell types could dif-
ferentiate into new plasma cells. Accordingly, bortezomib treat-
ment is able to result in long-lasting depletion of autoantibodies 
only if applied in combination with B  cell depletion (75, 76). 
The development of proteasome inhibiting drugs exhibiting 
fewer side effects than bortezomib might be necessary to allow 
application of therapeutic proteasome inhibition to a broader 
set of patients.
AUTOANTIBODY-INDUCED STIMULATION 
OF RECEPTORS
Grave’s Disease
Thyroid autoimmunity involves a breakdown in self-tolerance to 
Antibodies 
B cell
Plasma cell
Tfh cell
Antigen
Antigen-presentation
Priming
BCR and TLR 
mediated activation
Cytokines modulationg class switch
Antibody-mediated
inflammation
Antibody-mediated
protection
Cytokine
s modulationg class switch
FIGURE 2 | T/B cell cross talk in generating the autoimmune response. Autoantibodies can either promote or inhibit inflammation, depending on their 
immunoglobulin-isotype and glycosylation/sialylation patterns of their Fc-regions. Signals from both antigen-presenting B cells to T cells and from T cells to B cells, 
together, determine the inflammatory/anti-inflammatory property of the antibody response.
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and the thyroid-stimulating hormone receptor (TSHR) (77). 
Autoantibodies to TPO and/or thyroglobulin are invariably asso-
ciated with Hashimoto’s thyroiditis, but with a lower prevalence 
in Graves’ disease. Autoantibodies that arise spontaneously to 
the TSHR, the direct cause of Graves’ disease, have a number of 
unusual properties.
First, in Graves’ disease, TSAb mimic TSH and activate 
the TSH receptor in an unregulated manner, thereby causing 
hyperthyroidism (78) (Figure 3A). Transplacental transfer of 
TSAb in a mother with Graves’ disease may lead to transient 
neonatal hyperthyroidism (79). This confirms the role of 
TSAb in thyroid stimulation in  vivo. Second, the TSHR itself 
plays a role in the breakdown in self-tolerance to the receptor 
in genetically susceptible individuals. The highly glycosylated 
extracellular TSHR A-subunit, formed by intramolecular cleav-
age of the holoreceptor, is shed and is the autoantigen primarily 
responsible for TSAb induction in Graves’ disease (80–82) 
(Figure  3B). Third, in rare patients, non-activating TSHR 
autoantibodies can compete for TSH binding and block TSH 
stimulation [TSH blocking antibodies (TBAb)], thereby causing 
hypothyroidism with an atrophic goiter (83, 84) (Figure 3A). 
Hashimoto’s thyroiditis, which is a common autoimmune 
condition, may also lead to hypothyroidism by TPO-specific 
T  cells and possibly TPO autoantibody-mediated damage by 
NK cells and activation of the complement cascade (85). Fourth, 
the assays used to measure TSHR autoantibodies for clinical 
purposes are unusual. Unlike most autoantibodies that can 
be detected by enzyme-linked immunosorbent assay (ELISA) 
or western blotting (see below), pathogenic TSHR antibodies 
are measured by the inhibition of TSH binding to its receptor 
(“TBI”) or in bioassays involving the generation of cAMP from 
monolayers of TSHR-expressing cells (“TSAb” activity) (86). 
Fifth, in experimental models, TSHR autoantibodies induced by 
conventional immunization using TSHR protein and a variety 
of adjuvants do not stimulate the thyroid gland and do not 
induce experimental Graves’ disease (87). Instead, TSAb and 
Graves’-like hyperthyroidism can be induced in mice or ham-
sters by injecting intact eukaryotic cells expressing the TSHR 
or by injecting plasmid/adenoviral vectors encoding the TSHR 
or, more efficiently, its A-subunit (77, 87). Valuable monoclonal 
Thyroid
Thyroid follicle
TPO
Thyroglobulin
Graves disease
TSHR
Atrophic goiterHealthy
Euthyroid Hyperthyroid Hypothyroid
TSAb
Thyroid hormones
TSH
Thyroid hormones
TSH
TBAb
Cleavage region
Ectodomain
TSHR 
holoreceptor
Transmembrane domain with 7 helices
Shed TSHR
A-subunit
A
B
FIGURE 3 | Mechanisms in thyroid autoimmunity. (A) Location of the thyroid gland in relation to the larynx and trachea and schematic representations of a 
thyroid follicle in a healthy individual (cuboidal cells) with the location of the thyroid-stimulating hormone receptor (TSHR), thyroglobulin, and thyroid peroxidase 
(TPO); a stimulated follicle in a patient with thyroid-stimulating autoantibodies (TSAb) (Graves disease; columnar epithelial cells); and a follicle in a patient with TSH 
blocking antibodies (TBAb) (atrophic goiter; very thin epithelial cells). Thyroid hormones (T4, T3) are elevated and TSH levels are very low in Graves’ disease; 
conversely, T4 and T3 are low and TSH is elevated TSH levels in atrophic goiter. (B) Representation of the TSH holoreceptor including its transmembrane domain 
(left) and the TSHR A-subunit (right) shed after cleavage.
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antibodies (MAbs) have been isolated from mice immunized 
using these novel approaches (88, 89).
It should be noted that the human TSHR or its A-subunit are 
used for immunization in almost all studies. Mice immunized 
with adenovirus encoding mouse TSHR A-subunit fail to develop 
TSHR antibodies because of central tolerance to the endogenous 
TSHR. TSHR-deficient mice injected with adenovirus encoding 
mouse TSHR A-subunit develop TSHR antibodies (90). Adoptive 
transfer of splenic T cells from immunized TSHR-deficient donors 
to wild-type recipients on the same genetic background reveals 
the stimulatory ability of these induced TSHR autoantibodies 
(91). Finally, although TSHR autoantibodies are unusual, Graves’ 
hyperthyroidism is a common condition, with a prevalence of 
~1% (92). Moreover, TSHR autoantibodies play a role in Graves’ 
exophthalmos and Graves’ dermopathy by interacting with the 
TSHR expressed on orbital fibroblasts (93) and dermal fibroblasts 
(94). It is notable that patients with Graves’ exophthalmos and 
dermopathy usually have very high circulating levels of TSHR 
autoantibodies (94).
Properties of TSHR Autoantibodies
The immunological properties of TSAb and TBAb, based on 
patients’ sera and human MAbs derived from Graves’ patients, 
are described in detail elsewhere (95, 96). In brief, TSAb are 
present at very low (ng/ml) concentrations in serum (97–99). In 
contrast, TBAb are present at much higher concentrations, μg/ml 
(80, 99). TSHR autoantibodies are predominantly IgG although 
IgA- and IgE-class TSHR autoantibodies have been observed 
by flow cytometry (100). Both serum TSHR autoantibodies 
and human mAb have extremely high affinities, as would be 
expected for antibodies that compete with TSH for binding to 
its receptor. “Switching” from TBAb to TSAb (or vice versa) is 
a rare phenomenon observed in some patients. These changes 
involve differences in the concentrations of TSAb versus TBAb, 
as well as their affinities and/or potencies in individual patients 
(86). Anti-thyroid drugs or immunosuppression/hemodilution 
in pregnancy reduce initially low TSAb levels even further while 
higher concentration TBAb may persist. In contrast, if TSAb 
emerge during levothyroxine administration for TBAb-induced 
hypothyroid, these stimulating antibodies may be sufficient to 
swing the pendulum to hyperthyroidism.
Thyroid-stimulating autoantibodies and TBAb interact with 
conformational epitopes and do not bind to synthetic TSHR 
peptides. Crystallization of both types of mAb with recombinant 
TSHR-A-subunit protein reveal closely overlapping epitopes with 
subtle differences expected for a TSAb (M22) and a TBAb (K1-70) 
(101, 102). Unlike spontaneously arising TSHR autoantibod-
ies, some TSHR mAb derived from immunized hamsters bind 
to a linear peptide in the region deleted from the single chain 
TSH holoreceptor after intramolecular cleavage into A- and 
TABLE 2 | Selected drugs targeting autoantibody-induced pathology.
Drug/intervention Phase Target/mode of action Indications(s) Reference
Anti-CD20 (Rituximab) Clinical use CD20 (B cells) – Grave’s disease
– SSc
– TTP
– Vasculitis
– Pemphigus
(108)
(109)
Immunadsorption/
plasmapheresis
Clinical use Temporary removal of all antibodies – MG
– Pemphigus
– Pemphigoid
– TTP
– Autoantibody-induced carditis
(110)
IVIG Clinical use Several, inhibition of the FcRn reduced circulating 
autoantibodies
– MG
– Autoantibody-induced carditis
– Pemphigus
– NMOSD
(111)
Caplacizumab Clinical use Anti-von Willebrand nanobody – TTP (112)
Eculizumab Off label use C5 – Licensed for paroxysmal nocturnal 
hemoglobinuria
– Proof-of-concept study in NMOSD
(113)
SHP652 (SM101) Phase II Fc/FcγR interactions – Systemic lupus erythematosus
– Idiopathic thrombocytopenic purpura
(114)
R935788 Phase II SYK – Rheumatoid arthritis
– Pemphigoid (preclinical)
NCT00665626 
(115)
K1-70 Phase I Thyroid-stimulating hormone receptor antagonist Grave’s disease (116)
BAX930 Phase I BAX is recombinant ADAMTS13, given to reconstitute 
ADAMTS13
– TTP NCT02216084
CAAR T cells Preclinical Autoantigen-specific B/plasma cells – Pemphigus (117)
EGFR inhibition Preclinical EGFR – Pemphigus (118)
Tandem peptide Preclinical Tandem peptide consisting of 2 connected peptide 
sequences targeting the desmoglein-3
– Pemphigus (119)
Apremilast Preclinical PDE4 Inhibition – Licensed for psoriasis
– Preclinical evidence for pemphigoid
(120, 121)
SSc, systemic sclerosis; MG, myasthenia gravis; IVIG, intravenous immunoglobulin; PDE4, phosphodiesterase 4; FcRn, neonatal Fc-receptors; TTP, thrombotic thrombocytopenic 
purpura; NMOSD, neuromyelitis optica spectrum disorder; SYK, spleen tyrosine kinase; CAAR, chimeric autoantigen receptor T cells; EGFR, epidermal growth factor receptor.
References to websites were all accessed on April 28, 2017.
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B-subunits. These “neutral” or “cleavage region” TSHR antibod-
ies neither stimulate the thyroid nor block TSH stimulation but 
may play a role in signaling cascades leading to apoptosis (103). 
Because the epitope of these neutral antibodies (unlike TSAb and 
TBAb) is lost after TSHR cleavage into subunits, they can only 
interact with the single chain, uncleaved TSHR. Whether the 
TSHR in vivo exists in the uncleaved form has been the subject 
of debate (82). In human disease, confirmation of the existence 
of neutral TSHR autoantibodies will require information on their 
concentrations or affinities. To date, no human “neutral/cleavage” 
TSHR autoantibodies have been cloned.
Current and Future Approaches to Treat Graves’ 
Disease
Several approaches are available to treat the hyperthyroidism 
in Graves disease including thionamide drugs, thyroid ablation 
by Radioiodine (131-I), or subtotal thyroidectomy as well as 
β-blockers to inhibit the actions of excess thyroid hormone (104). 
In general, these therapies are effective, thionamide drugs are 
inexpensive, and all approaches have been used for many years. 
Radioiodine therapy frequently leads to permanent hypothyroid-
ism, subsequently leading to life-long thyroid hormone replace-
ment. Rarely, development of serious side effects with thionamide 
drugs requires one of the alternative forms of treatment. Atrophic 
goiter is treated by replacement of thyroid hormone (levothyrox-
ine, LT4), which is safe and inexpensive.
Three novel forms of therapy for Graves’ hyperthyroidism 
are currently under investigation: (i) small molecule inhibitors 
of TSHR function (105–107), (ii) monoclonal TBAb, such as 
K1-70 (96) that block the binding and function of TSAb, and 
(iii) inhibitors of components of the adaptive immune system, 
such as rituximab, which targets B-lymphocytes prior to their 
maturation into plasma cells (Table 2).
Small molecule inhibitors and monoclonal TBAb target the 
proximate cause of hyperthyroidism, the TSHR. Both of these 
new forms of therapy, if successful, are likely to be more expensive 
than the presently available and effective therapies. In addition, 
because small molecule inhibitors interact with the heptahelical 
transmembrane domain of the TSHR, this treatment option car-
ries the risk of side effects consequent to potential cross-reactivity 
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with others in the very large G-protein-coupled receptor family. 
Graves’ ophthalmopathy occurs with varying degrees of severity 
and can be very distressing symptomatically and cosmetically, as 
well as (fortunately rarely) leading to loss of vision. Options for 
the treatment of Graves’ ophthalmopathy include, in addition 
to the restoration of the euthyroid state, corticosteroids, orbital 
irradiation, and orbital surgical decompression. Because none of 
these therapeutic modalities are optimal, there is presently much 
interest in the use of antibodies to CD20 (rituximab) that cause 
B cell depletion. Two recent double-blind clinical trials with rituxi-
mab have been reported: in patients with long-standing Graves’ 
eye disease (10 months), rituximab was no more effective than 
control saline injections (122). In contrast, in patients in whom 
eye disease duration was short (4.5 months), rituximab was more 
effective at reducing clinical symptoms than methylprednisone 
(123). The different outcomes of these two studies emphasize the 
importance of early intervention, which, in turn, requires early 
disease diagnosis.
The challenge in Graves’ disease is to specifically inhibit the 
development, or ongoing production, of TSHR autoantibodies. 
Such an approach has been attempted in mouse models of induced 
Graves’ disease. First, injecting neonatal BALB/c mice with TSHR 
A-subunit protein induced tolerance that could not be broken by 
subsequent immunization with adenovirus encoding A-subunit 
(124). Second, hyperthyroidism was attenuated in adult mice by 
injecting TSHR A-subunit protein before A-subunit adenovirus 
immunization. The latter involved deviating pathogenic antibod-
ies to non-functional antibodies and was only effective if applied 
before immunization, not after hyperthyroidism had been 
established (125). However, in a mouse model that spontaneously 
develops pathogenic TSHR antibodies (126), injecting TSHR 
A-subunit protein failed to divert the autoantibody response to 
a non-pathogenic form, highlighting critical differences between 
induced and spontaneous Graves’ disease models, with implica-
tions for potential immunotherapy in humans (127).
Systemic Sclerosis (SSc)
Systemic sclerosis or scleroderma is one of the most lethal 
rheumatic diseases characterized by microvascular dysfunction, 
dysregulation of innate and adaptive immunity, and interstitial 
and perivascular fibrosis in the skin and internal organs (128). 
Mechanistically, a hallmark SSc feature is the presence of high 
serum concentrations of multiple autoantibodies (129). Among 
these autoantibodies, increased titers of stimulating autoanti-
bodies targeting both angiotensin II type 1 receptor (AT1R) 
and endothelin-1 type A receptor (ETAR) have been reported to 
contribute to SSc pathogenesis and suggested as biomarkers for 
risk assessment of disease progression (130). These antibodies 
can be detected by ELISA (see below). Anti-AT1R and anti-
ETAR are strong predictors of digital ulcers development (131), 
they can be considered as predictive and prognostic biomarkers 
of (SSc)-associated pulmonary arterial hypertension (132) and 
are linked to the development of lung fibrosis and vasculopa-
thies in patients with SSc (133). Data from mice models show 
that anti-AT1R and anti-ETAR antibody-positive SSc-IgG 
cause structural alterations of the lungs including induction of 
interstitial lung disease and obliterative vasculopathy, increased 
cellular density, and enhanced interstitial cellular infiltrations 
following passive transfer of IgG from SSc patients to wild-type 
mice (134, 135).
Autoantibodies targeting ETAR and AT1R increase the sen-
sitivity of both AT1R and ETAR to their natural ligands (angio-
tensin II and endothelin-1) and have synergistic effects in the 
presence of these ligands (132, 136). Anti-AT1R and anti-ETAR 
autoantibodies activate signaling molecules and transcription 
factors such as protein kinase C-α (PKC-α), extracellular signal-
regulated kinase 1/2, nuclear factor-κB (NF-κB), and activator 
protein 1, which are involved in several pathophysiologic pro-
cesses (130, 136–138). Increased number of reports have recently 
linked a variety of anti-AT1R and anti-ETAR cellular and systemic 
effects to SSc pathogenesis (139). Among them, anti-AT1R and 
anti-ETAR from SSc patients (SSc-IgG) contribute to vasculopa-
thies by regulating cell migration through interleukin-8 (IL-8) 
production and expression of vascular cell adhesion molecule-1 
by human microvascular endothelial cells (HMEC-1). Consistent 
with these findings, IL-8 release by PBMCs, regulation of wound 
repair, and T-cell chemotaxis have been also observed following 
IgG-induced ETAR and AT1R activation (133, 134). Anti-AT1R 
and anti-ETAR autoantibodies directly induce collagen pro-
duction by skin fibroblasts (134) and regulate the synthesis of 
profibrotic factors such as transforming growth factor β (TGF-β) 
by human dermal microvascular endothelial cells (130), which 
are pathological mechanisms in SSc patients who develop 
lung fibrosis. Another important mechanism of autoantibody-
induced pathology triggered by anti-AT1R and anti-ETAR is 
the production of chemokine (C-C motif) ligand 18 (CCL18) 
(133). CCL18 levels in bronchoalveolar fluid and sera directly 
reflect pulmonary fibrotic activity and are predictive for lung 
disease progression and mortality in patients with SSc (140–142). 
Additional pathological mechanisms triggered by anti-AT1R and 
anti-ETAR have been reported such as the increase of neutrophil 
migration and reactive oxygen species (ROS) production by 
neutrophils (134). An overview of the pathological mechanisms 
triggered by anti-AT1R and anti-ETAR autoantibodies is shown 
in Figure 4.
In addition to the levels of anti-AT1R and anti-ETAR autoan-
tibodies, AT1R and ETAR expression needs to be considered in 
SSc pathogenesis. The cellular effects triggered by anti-AT1R 
and anti-ETAR autoantibodies depend on the AT1R and ETAR 
expression levels. For instance, imbalanced AT1R/AT2R and 
ETAR/ETBR expression ratios in SSc influence autoantibody-
mediated effects such as secretion of profibrotic CCL18 (143). So 
far, a therapy that specifically inhibits anti-AT1R and anti-ETAR 
autoantibodies or/and regulates AT1R/AT2R and ETAR/ETBR 
expression is not available. Expansion of the currently state of 
knowledge about the cell signaling pathways and mechanism of 
autoantibody-induced pathology triggered by anti-AT1R and 
anti-ETAR will be essential to develop new therapies specifi-
cally targeting autoantibody effects simultaneously maintaining 
the renin–angiotensin and endothelin systems physiological 
response. Achieving this goal will be essential for the manage-
ment of SSc patients in order to improve their quality of life and 
reduce SSc mortality rates. This achievement will also provide 
new therapeutic options for other diseases in which high 
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FIGURE 4 | Overview of mechanisms by which anti-AT1R and anti-ETAR induce systemic sclerosis (SSc) pathogenesis. (A) In vitro and (B) in vivo effects 
of autoantibodies targeting ETAR and AT1R in SSc are shown. Abbreviations: AT1R, angiotensin II type 1 receptor; ETAR, endothelin-1 type A receptor; PKC-α, 
protein kinase C-α; ERK1/2, extracellular signal-regulated kinase 1/2; NF-κB, nuclear factor-κB; AP-1, activator protein 1; TGF-β, transforming growth factor β; 
CCL18, chemokine (C-C motif) ligand 18; VCAM-1, vascular cell adhesion molecule-1.
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circulating levels of anti-AT1R and anti-ETAR autoantibodies 
have pathological effects (138, 144–148).
DISRUPTION OF NEURAL TRANSMISSION 
BY AUTOANTIBODIES
Myasthenia Gravis (MG)
Myasthenia gravis is an uncommon autoimmune disorder 
characterized by muscle weakness and abnormal fatigability that 
worsens with use of affected muscles and improves with rest. It 
is caused by the presence of autoantibodies to components of 
the postsynaptic muscle endplate localized at the neuromuscular 
junction (149, 150). The annual incidence of MG is approxi-
mately 1.7–34 per million, and the prevalence ranges from 15 
to 320 per million population (151–153). However, MG remains 
underdiagnosed and the prevalence shows a steady increase over 
time, which is likely reflective of better recognition of the condi-
tion, aging of the population, and the longer life span of patients, 
possibly due to improved disease treatment.
Myasthenia gravis is a chronic affliction that affects people of 
all ages and both sexes (154). Studies of large groups of patients 
show that the age of onset is characterized by a bimodal distribution 
with female predominance in the second to third decade of life 
and slight male predominance in the sixth to eighth decades. MG, 
especially early-onset MG, is often associated with other autoim-
mune diseases, most commonly autoimmune thyroid disease, 
SLE, RA, Addison’s disease, Guillain–Barré syndrome, type 1 
diabetes mellitus, and NMO (155).
Several subgroups of MG have been identified based on clini-
cal presentation, age of onset, autoantibody profile, and thymic 
pathology. Over two-thirds of all patients with MG begin with 
symptoms relating to their eye muscles (156). The symptoms usu-
ally progress to other muscles during the first 2 years, resulting 
in generalized MG. In about 15% of MG patients, symptoms are 
restricted to the eye muscles, and this condition is termed ocular 
MG. In most cases, a specific cause of MG cannot be identified 
(157). There is strong evidence that the pathogenesis of MG 
involves a combination of multiple genotypes of low penetrance 
and largely unidentified environmental factors (158). Patients 
with early-onset MG are usually associated with HLA-B8DR3 and 
thymic hyperplasia (155, 159). Approximately 15% of patients 
with MG have a thymoma, and 50% of thymoma patients develop 
MG (160). Improving the clinical symptoms by thymectomy in 
some MG patients, although questioned by many, also suggests a 
specific role of the thymus in MG (161, 162).
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About 90% of generalized MG is caused by pathogenic 
autoantibodies to muscle nicotinic AChRs. MG patients who 
do not have detectable autoantibodies to AChRs are referred 
to as seronegative. For many years, the cause of MG remained 
a mystery. In 1960, Simpson suggested that MG was caused by 
autoantibodies to AChRs acting as competitive antagonists (163). 
In 1973, Patrick and Lindstrom demonstrated that MG is an auto-
immune disease by showing that rabbits immunized with muscle-
like AChR purified from fish electric organ developed MG-like 
symptoms (164). Experimental autoimmune MG (EAMG) in 
rabbits, was reproduced in other species, especially inbred Lewis 
rats where the most detailed studies have been completed (165). 
EAMG shares many clinical and immunopathological features 
with those of MG. Clinical, electrophysiological, histological, 
pharmacological, and immunological analysis of EAMG led to 
extensive understanding of the pathological mechanisms in MG 
(150, 166). These findings promoted the use of immunosuppres-
sive treatments in MG.
The pathogenic role of autoantibodies to AChRs is clearly 
established. Most patients with MG have circulating antibodies 
to AChR (167). Injection of patients’ IgG or isolated autoanti-
bodies to AChR from patients into laboratory animals passively 
transfers several features of MG from human to the recipients 
(168, 169). Immune complexes (IgG and complement) co-
localize with AChRs on the postsynaptic membrane (170, 171). 
Plasmapheresis that removes circulating antibodies leads to a 
substantial, but temporary, improvement in muscle function 
(172). EAMG can be induced by immunization with purified 
AChR (164) or by injection of mAbs to AChR (173). However, 
among MG patients, there is not a close correlation between the 
absolute concentration of autoantibodies to AChR and sever-
ity (167, 174). Variability in specificities, affinity, and isotypes 
of the autoantibodies to AChR may contribute to this lack of 
correlation (175).
Autoantibodies to AChR can differ in their isotype, affinity, and 
specificity to various AChR epitopes. Pathological autoantibodies 
are directed at conformation-dependent extracellular epitopes 
of AChRs, especially the main immunogenic region (MIR) on 
AChR α1 subunits (176). Half or more of the autoantibodies 
to AChR in MG target the MIR. These autoantibodies impair 
neuromuscular transmission primarily by two mechanisms: 
(1) focal complement-mediated lysis of the postsynaptic mem-
brane that destroys AChRs and disrupts synaptic morphology 
(166, 171), (2) cross-linking AChRs by the autoantibodies on the 
surface of postsynaptic membrane accelerating endocytosis and 
lysosomal destruction of AChRs, termed antigenic modulation 
(177) (Figure 5). Some autoantibodies inhibit AChR function by 
direct blockage of acetylcholine (ACh) binding sites, but these 
appear to play a minor role (178). No cellular infiltration at the 
target muscle tissue of MG patients indicates that tissue damage 
is not caused by direct harmful effects of cytotoxic cells (170). 
However, autoreactive T cells provide help to B cells that produce 
autoantibodies to AChR (179). Autoantibodies directed at cyto-
plasmic epitopes of human AChR are also present in MG sera 
(180). However, these autoantibodies are not pathogenic because 
the cytoplasmic domain of AChR is not accessible to these 
autoantibodies in intact muscle. Additionally, rats repeatedly 
immunized with the cytoplasmic domains of AChR in adjuvant 
do not develop EAMG and serum antibodies from these rats do 
not bind the MIR, passively transfer EAMG, or cause antigenic 
modulation of AChR, although these antibodies bind to solubi-
lized native AChRs (175, 181).
In MG patients, the predominant isotypes of autoantibodies 
to AChR are IgG1 and IgG3, which fix complement (182). A series 
of studies have suggested that accumulation of autoantibodies to 
AChR and subsequent activation of the complement cascade 
on postsynaptic membrane result in the assembly of membrane 
attack complex (MAC), thereby destroying AChRs and disrupting 
synaptic morphology (166, 171, 183) (Figure 5). It seems likely 
that complement-mediated destruction of the postsynaptic mus-
cle membrane is more pathologically significant than antigenic 
modulation in MG pathogenesis (175, 184). These findings have 
promoted the development of novel therapies based on inhibition 
of complement pathways in MG treatment (185).
Half of AChR seronegative patients have antibodies to muscle-
specific kinase (MuSK), which is a component of the agrin recep-
tor complex that mediates clustering and stabilization of AChR in 
developing muscle (186). Autoantibodies to MuSK and those to 
AChR rarely coexist in the same patient. MuSK-related MG differs 
from AChR-related MG primarily by demonstrating more focal 
involvement and wasting of the involved muscles (187). This type 
of MG is predominantly in females and usually reported in adults. 
There is a HLA association with HLA-DQ5 (188). No thymus 
pathological changes have been reported and patients usually 
have no response to thymectomy (189). Autoantibodies to MuSK 
are mainly of the IgG4 isotype, which does not activate comple-
ment, and the IgG4 fraction alone is sufficient for passive transfer 
of the disease (188). Autoantibodies to MuSK directly suppress 
the postsynaptic tyrosine kinase pathway thus indirectly reduce 
the metabolic stability of endplate AChRs (190). Complement 
is not necessary for pathogenesis in mice (191). Patients with 
MuSK-related MG respond better to plasmapheresis than to 
intravenous immunoglobulin (IVIG) (192). Rituximab appears 
to be more effective in patients with MuSK-related MG than in 
patients with AChR-related MG (193).
Low-density lipoprotein receptor-related protein 4 (LRP4), 
which belongs to a family of the low-density lipoprotein recep-
tor family, is a receptor for nerve-derived agrin and an activator 
of MUSK, and is necessary to maintain AChR function (194). 
Autoantibodies to LRP4 have been detected in some of double-
seronegative MG patients who do not have antibodies to AChR 
or MuSK (195, 196). LRP4-related MG has a female preponder-
ance. Most of these patients present with ocular or generalized 
mild MG. This type of MG appears to be clinically similar to 
AChR-related MG, but there is no clear role for thymectomy. 
Autoantibodies to LRP4 are predominantly of the IgG1 isotype, 
which fixes complement, and thus may damage the postsynaptic 
muscle membrane by a similar mechanism as those to the AChR. 
Inhibition of argin-induced AChR clustering may also be a poten-
tial pathophysiological mechanism (197).
Some seronegative patients have low-affinity antibodies to 
AChR that are not detectable by the classical immunoprecipita-
tion assay. These autoantibodies can be identified by cell-based 
assay (CBA) only (198). These patients are similar to patients 
FIGURE 5 | Schematic illustration of the two major pathogenic mechanisms of autoantibodies to acetylcholine receptor (AChR). (1) Autoantibody 
binding to the AChR on the surface of postsynaptic muscle membrane activates the complement cascade, resulting in the formation of membrane attack complex 
(MAC) and localized destruction of the postsynaptic membrane. The immune assault releases shedding of membrane fragments containing AChRs into the synaptic 
cleft, and leads to a simplified, altered morphology of the postsynaptic membrane. (2) Autoantibodies cross-link AChR molecules on the postsynaptic muscle 
membrane, causing endocytosis of the cross-linked AChR molecules and their degradation (antigenic modulation). This leads to a reduced number of AChR 
molecules on the postsynaptic membrane.
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with AChR-related MG with respect to their clinical presenta-
tion, their response to treatment, and their thymic abnormalities. 
Some seronegative patients probably have pathogenic antibodies 
to as-yet-unidentified antigens in the postsynaptic membrane. 
Antibodies to agrin and cortactin are often identified in combina-
tion with other autoantibodies (199). Their contribution to MG 
pathogenesis is still unclear. Some patients with AChR-related 
MG have antibodies to titin and ryanodine receptor (200). These 
antibodies cannot enter the muscle cell in vivo and thus might 
not cause any muscle weakness, but rather could be markers of 
the autoimmune disease directed at muscle surface resulting in 
exposure of cytoplasmic proteins.
Treatment options available today rely primarily on a com-
bination of symptomatic therapies and general, non-specific 
immunosuppression. Many MG patients respond favorably to 
treatment (149). Symptomatic treatment of MG with acetyl-
cholinesterase inhibitor temporarily enhances neuromuscular 
transmission by increasing the availability of ACh to compensate 
for loss of AChRs, but does not induce complete or sustained 
relief of MG symptoms in most patients and does not alter disease 
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progression (149, 154). Patients with MuSK-related MG may not 
respond to cholinesterase inhibitor. At high doses, cholinesterase 
inhibitor may actually cause more muscle weakness through 
desensitization of AChRs (201). Most patients require additional 
immunosuppressive treatment. High doses of corticosteroids and 
chronic treatment with non-specific immunosuppressive drugs 
are usually required to maintain disease control. Non-specific 
immunosuppressive drugs primarily suppress lymphocyte activa-
tion and proliferation and have little effect on long-lived plasma 
cells that are terminally differentiated cells and continue produc-
ing pathogenic antibodies (202). Therefore, the use of these drugs 
is often hampered by delayed clinical response. Plasmapheresis 
and IVIG are used for acute severe exacerbations in generalized 
MG. For a chronic disease like MG, the current treatment has a 
high cost (203), as most patients during the long-term treatment 
suffer several undesirable side effects (204). A distinct subset of 
patients often referred to as having refractory MG, do not respond 
well to current treatments (205).
Advances in understanding of the pathogenesis of the various 
forms of MG and breakthrough use of mAbs specific for different 
aspects of the immune system involved in antibody production 
and antibody-mediated tissue damage provide an opportunity 
to develop more specific treatment with long-lasting benefits 
and fewer adverse effects. Rituximab, a chimeric murine-human 
mAb that depletes B  cells by binding to their CD20 surface 
marker, has been reported to be effective in patients with severe 
or refractory MG, especially in those with MuSK-related MG 
(193, 205). Yale University is sponsoring a multicenter clinical 
trial (NCT02110706) to determine whether rituximab is a safe 
and beneficial therapeutic for MG. BAFF is a potent survival 
factor for B cells and belimumab, a human mAb targeting BAFF, 
reduces B  cell activation and differentiation into antibody-
producing plasma cells. A phase II study of belimumab in 
AChR- and MuSK-related MG is in progress (NCT01480596). 
A placebo-controlled phase II study in patients with refractory 
generalized MG has shown that eculizubmab, a humanized mAb 
against C5 complement, is effective, promoting an ongoing phase 
III study (NCT01997229). Additionally, a trial of hematopoietic 
stem cell therapy in MG patients is in progress (NCT00424489).
Like many autoimmune diseases described in this review, MG 
is an ideal disease for antigen-specific immunotherapy because of 
its clearly defined autoantigen. Theoretically, an antigen-specific 
immunotherapy would eliminate the pathogenic autoimmune 
response to autoantigen specifically without affecting the other 
functions of the immune system, and thus avoiding severe 
adverse effects. Such antigen-specific immunosuppressive 
therapy is not yet available for MG (206). The idea of specific 
immunosuppression of autoimmune response to AChR by 
administration of AChR peptides or fragments has been investi-
gated in EAMG for many years (181). However, translation into 
the clinic has been hampered by concerns about the potential 
for exacerbation of pathogenic autoimmune response, because 
the rationale behind these studies is based on a hypothesis that 
specific immunosuppression of autoimmune response requires 
the use of disease-inducing sequences (207). Recently, a vaccine 
using AChR cytoplasmic domains has been shown to be effective 
at specifically suppressing EAMG (175, 181, 208). Immunization 
with the vaccine in adjuvant prevents development of chronic 
EAMG, rapidly inhibits established EAMG, and prevents rein-
duction of EAMG for at least 6 months. Therapeutic effects might 
result from inhibition of production of pathological antibodies 
by a combination of antibody-mediated feedback suppression 
(Figure  6) and regulatory T  cell-mediated active suppression. 
These studies indicate that not all autoantibodies are harmful. 
Autoantibodies to AChR cytoplasmic domain may play a thera-
peutic role in the antigen-specific immunotherapy. This approach 
may be applicable to other antibody-mediated autoimmune 
responses to other transmembrane proteins.
Anti-NMDA Encephalitis
The recently discovered anti-N-methyl-d-aspartate-receptor 
(NMDAR) encephalitis—is the most common antibody-
associated acute autoimmune encephalitis (209). Incidence has 
been estimated at 3–5/1.000.000/year (210). Although a rare 
disease, its description has greatly influenced neuroimmunology 
and neuroscience. It represents a model disease for a group of 
syndromes characterized by detection of autoantibodies targeting 
synaptic structures, hence called synaptic encephalitis (211).
Anti-NMDAR encephalitis preferentially occurs in young 
adults and children, predominantly women (80%). Approximately 
70% of the patients develop prodromal symptoms, e.g., headache 
or fever, followed by rapid change of behavior including anxiety, 
hallucinations, and psychosis. Abnormal movements (orofacial 
dyskinesias, chorea, stereotyped movements) and eventually 
decrease of consciousness, coma, and severe global autonomic 
dysregulation (sometimes leading to hypoventilation and asys-
tolia) ensue. Seizures and status epilepticus may occur at any 
stage of the disease. Brain MRI is normal in most but cerebro-
spinal fluid (CSF) shows non-specific inflammatory changes in 
almost all cases. Around 40% of the patients have an underly-
ing neoplasm. The majority of tumors are ovarian teratomas. 
Approximately, 50% of patients respond well to IVIGs, steroids, 
or plasma exchange and the other 50% require rituximab alone or 
combined with cyclophosphamide. During recovery and after the 
acute symptoms have resolved, patients continue with deficits of 
memory and attention, impulsivity, behavioral disinhibition, and 
executive dysfunction that usually improve over many months. 
However, in some patients, recovery is incomplete, may take 
years, and mortality due to intensive care complications can be 
as high as 7% (212–214).
Diagnosis of anti-NMDAR encephalitis relies on the detec-
tion of IgG autoantibodies targeting a highly conserved and very 
restricted epitope on the aminoterminal-domain of the GluN1 
subunit of the heterotetrameric ionotropic glutamate receptor 
NMDAR in patients’ CSF and serum by indirect fluorescence 
or ELISA (212, 215). A strong line of experimental and clinical 
evidence has been gathered, showing that NMDAR autoantibod-
ies directly—without any other humoral or cellular components 
of the immune system involved—and reversibly interfere with 
NMDAR mediated synaptic function and disrupt central nervous 
system network function.
The pathophysiology of anti-NMDAR encephalitis can be 
divided into (1) initiation of systemic immune response, (2) 
propagation of antibody-producing cells into the central nervous 
FIGURE 6 | Schematic illustration of mechanism of antibody-mediated feedback suppression. Cross-linking of the B-cell receptor and the inhibitory IgG 
receptor (FcγRIIB) on the B cell surface by antigen–antibody complex may result in apoptosis of antigen-specific B cells, inhibition of B cell activation by helper 
T cells, and inhibition of B cell proliferation. Cross-linking FcγRIIB on the surface of plasma cells by immune complexes induces apoptosis of plasma cells.
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system, and (3) effects of the antibodies on synaptic function 
(Figure 7).
(1) In paraneoplastic anti-NMDAR encephalitis, ovarian terato-
mas show ectopic expression of NMDAR and a dense infiltrate 
of T-, B-lymphocytes, and macrophages together with com-
plement deposition in the tumors (212). The tumor-induced 
inflammation likely provides co-stimulation to autoreactive 
NMDAR specific T- and B-lymphocytes causing a breach 
of endogenous tolerance, systemic immune response, gen-
eration of plasma cells, and autoantibodies (Figure 7, steps 
1–3). However, not all ovarian teratomas induce NMDAR 
antibodies presumably due to tumor-intrinsic and host-
intrinsic factors (e.g., MHC class II haplotypes) (Figure 7A) 
(217). The initial trigger in idiopathic cases is currently 
unknown (Figure  7B). Interestingly, HSV-1 encephalitis 
can induce secondary anti-NMDAR encephalitis (218–222), 
and further post-infectious encephalitis variants are emerg-
ing (e.g., Japanese B-encephalitis). Furthermore, idiopathic 
anti-NMDAR encephalitis appears to occur seasonally in 
children (223). Thus, it is intriguing to speculate that in some 
“idiopathic” cases, yet unidentified viral infections might 
prove to be a trigger of anti-NMDAR encephalitis.
(2) A systemic NMDAR-directed immune response by itself 
does not appear to be sufficient to cause symptoms (Figure 7, 
step 4). Serum NMDAR antibodies can persist long after 
symptoms have resolved and serum titers do not correlate 
well with symptoms (224). The intact blood–brain barrier 
(BBB) prevents systemic antibodies and complement from 
reaching the synapse [CNS IgG levels are 400-fold lower than 
in serum (225)]. However, CSF NMDAR titers are correlated 
with disease activity (224). They are produced by dense 
infiltrates of plasma cells found perivascular in the CNS 
(Figure 7, steps 6–8) (226). The driving force behind estab-
lishing these CNS-local plasmablasts and -cells is unknown. 
A “second hit” hypothesis postulates a secondary infectious 
or inflammatory condition attracting preexisting NMDAR-
antibody-producing cells to the CNS (Figure  7, step 5). 
Some support to this hypothesis is provided by detection of 
high levels of the B-cell-attracting chemokine CXCL13 in 
the CSF of anti-NMDAR encephalitis patients (227). Other 
chemokines and cytokines are also likely to be involved. 
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FIGURE 7 | Pathophysiology of anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis. Details are explained in the text, where the numbering 
corresponds to the labeling used here. In brief, ectopic expression of NMDA receptors in ovarian teratomas together with co-stimulatory signals (A) or unknown 
triggers (B) lead to systemic immune response and formation of antigen-specific circulating B-, T-, and plasma cells producing NMDAR antibodies (1–4). The latter 
do not reach neurons in sufficient concentratiosn to exert effects due to the blood–brain barrier (dashed line). An unknown secondary trigger (e.g., systemic 
infections, 5) eventually mediates transition of B-, T-, and plasma cells into the brain. The resulting antibody production effectively increases intrathecal NMDAR 
antibody concentration above a threshold overwhelming neuronal compensation mechanisms and leading to net loss of surface NMDAR resulting in neurological 
symptoms. Adapted from Moscato et al. (216).
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Elucidation of the responsible “second hit,” the chemokines 
involved and the possible contribution of T-lymphocytes 
and long-lived plasma cells hidden behind the BBB would 
provide a new angle and rationale for treatment of patients, 
e.g., IL6-directed treatment or proteasome inhibitor treat-
ment. It might furthermore help to explain the beneficial 
effects of the CD20-antibody rituximab in this condition in 
spite of its inability to cross the intact BBB.
(3) For anti-NMDAR encephalitis, a direct pathogenic role of 
GluN1 IgG antibodies has been established in cultures of 
neurons and after cerebroventricular infusion of patients’ 
antibodies to rodents (Figure 7, step 9). The antibodies are 
mainly composed of complement-fixing IgG1 and IgG3 
isotypes, yet complement deposition is not a pathological 
feature of the disease (228–230). This is likely due to the low 
concentration of complement components in the CSF. Using 
cultured neurons, patients’ antibodies cause cross-linking 
and selective internalization of NMDARs that correlate with 
the antibody titers. These effects were reversible after remov-
ing the antibodies and dependent on the cross-linking ability 
but not the Fc-terminus of the antibodies (230). In contrast to 
the intense effects on NMDAR, patients’ antibodies did not 
alter the localization or expression of other synaptic proteins, 
number of synapses, dendritic spines, dendritic complexity, 
or cell survival (216, 231, 232). A transfer murine model 
using continuous ventricular infusion (14 days via osmotic 
pumps) of CSF from patients with anti-NMDAR encephalitis 
showed profound effects on memory and behavior in parallel 
to progressive hippocampal antibody binding and a decrease 
of total and synaptic NMDARs, without affecting PSD95 
or AMPAR. These effects gradually improved after stop-
ping the antibody infusion, with reversibility of symptoms 
accompanied by restoration of NMDAR levels, establishing 
the pathogenicity of the antibodies (233). A need to develop 
new therapies targeting this direct pathogenic effect of 
autoantibodies derives from the fact that some patients 
suffer from severe symptoms and prolonged intensive care 
treatment in spite of aggressive immunosuppressive therapy. 
In these, long-lasting and therapy-refractive local autoanti-
body production in the CNS by plasma cells hidden within 
the BBB might be the cause (224). Future therapies could 
(1) interfere with binding of NMDAR-antibodies to its target 
antigen as has been successfully shown in  vivo with the 
co-administration of Ephrin-B2 in an animal model (234); 
(2) apply BBB-permeable decoy approaches reducing effec-
tive NMDAR-antibody burden in the CNS; and (3) counteract 
symptoms via modulating antagonistic neurotransmitters to 
rebalance disturbed network functions.
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Induction of Structural Changes and 
Alterations in Signaling by Autoantibodies 
in Pemphigus Diseases
Epidemiology, Clinical Presentation, Histology,  
and Immunohistology of Pemphigus
Pemphigus diseases are a group of rare, but prototypical autoim-
mune blistering, skin conditions with autoantibodies against 
defined structural antigens of epidermal keratinocytes (235). 
There are two major types of pemphigus diseases, pemphigus 
vulgaris (PV) and pemphigus foliaceus (PF). The incidence 
depends on the population and is 1.6 per 100,000 adults in the 
Jerusalem area (236), but 0.7 for the total UK population (237) 
in PV. For PF, there is an endemic form (i.e., fogo selvagem) in 
Brazil, accounting for an incidence of 1–4 cases per 1,200 person 
years (238). Clinically, in PV, oral mucous membranes are usually 
affected, with facultative involvement of the skin (235). Affections 
in PF are only seen on the skin and blisters are even more fragile. 
Here, patients usually present with scaly crusted lesions, because 
blisters break very early after formation (235).
Histologically, pemphigus lesions show loss of intercellular 
adhesion of epidermal keratinocytes (239). All patients show 
intercellular staining of IgG within a biopsy of perilesional epi-
dermis, whereas more than 80% of patients feature circulating 
IgG directed against keratinocyte surfaces in their serum (240). 
Multiple lines of evidence exist for the finding, that the main anti-
gens targeted in pemphigus are desmogleins (Dsgs), desmosomal 
transmembrane glycoproteins that mediate epidermal cell–cell 
adhesion, and different expression (and compensation) of Dsg3 
and Dsg1 within epidermis and mucous membranes explains 
the localization of blisters in PV and PF patients (235, 240, 241). 
Other antigens targeted in a minority of pemphigus patients 
may include other desmosomal cadherins (e.g., desmocollins, 
Dscs), classical cadherins or even other autoantigens (242–248). 
Knowledge of these antigens targeted in pemphigus patients 
allowed for development of serological tests as immunofluo-
rescence and ELISA, and titers measured usually correlate with 
disease activity (see below) (249–251).
Brief Overview on Standard Treatment Options  
in Pemphigus
Standard present treatment is reviewed extensively elsewhere 
(235, 252), but critically depends on immunosuppression and 
modulation. Corticosteroids are effective within days when given 
systemically, likely because of increased synthesis of targeted Dsgs 
by keratinocytes, counteracting the desmosome-depleting effects 
of anti-Dsg antibodies in patients (253). Anti-CD20 therapy with 
rituximab represents potentially very effective therapy, leading to 
complete remission off all therapy in about 90% of pemphigus 
patients treated with one or more cycles of intravenous CD20+ 
B-cell-depleting rituximab (109). All of these options have their 
own limitations and challenges, and there are patients resist-
ant to multiple regimens of therapy illustrating the need for a 
better understanding of the pathophysiology of pemphigus on 
a molecular level -including signaling pathways implicated into 
autoantibody-induced blistering- hopefully resulting in more 
specific therapy.
Autoantibodies Alone Cause Skin Pathology  
in Pemphigus
Early experiments using passive transfer of human IgG from 
pemphigus patients into mice demonstrated dose-dependent 
recapitulation of human pathology (254). Disease induction is 
possible with bivalent F(ab′)2 and monovalent Fab′ fragments 
purified from PF patients’ sera as well with monovalent scFv frag-
ments cloned by antibody phage display from pemphigus patients 
(255–258). Consequently, Fc-dependent mechanisms are dispen-
sable in pemphigus pathophysiology, and autoantibodies directly 
mediate disease by interfering with the interaction of desmoglein 
molecules on the outside of keratinocytes, either by interference 
with homophilic trans- or cis-interaction of Dsg molecules 
(Figure 8) (259–261). Further evidence for direct interference 
with adhesion comes from epitope-mapping studies of pem-
phigus autoantibodies on domain-swapped and point-mutated 
Dsg1/Dsg3 molecules, mapping most of the dominant epitopes 
bound by patients’ sera to the aminoterminal ectodomains of 
Dsg1/3, which are critical for adhesion (262). Finally, pemphigus 
antibodies bind to calcium-dependent conformational epitopes, 
something seen in adhesion mediated by cadherins as well, again 
suggesting that patients’ autoantibodies do bind to domains 
important for adhesion. Interestingly, Dsg3-specific T cells have 
also been demonstrated to cause cutaneous pathology by induc-
ing interface dermatitis when injected into lymphocyte-deficient 
mice (263).
Clustering, Internalization, and Depletion  
of Desmosomal Dsgs by Autoantibodies
Various researchers have been proposing other models, which 
are most likely not opposing the model of steric hindrance but 
rather complementing observed pathologies in pemphigus: the 
Dsg non-assembly depletion hypothesis describes how divalent 
anti-Dsg antibodies cross-link and cluster Dsgs, leading not only 
to internalization of non-junctional membrane-bound Dsgs but 
also resulting in prevention of incorporation of newly synthesized 
Dsgs into forming desmosomes (264, 265). Consequently, des-
mosomes become depleted of Dsgs and fail to provide adhesion. 
This model is supported by data from patients and from cell 
culture experiments, showing clustering of Dsg3/1 by Dsg3/1-
specific autoantibodies (266–268), and by the observation that 
forced expression of Dsg3 by adenoviral delivery can prevent 
autoantibody-mediated Dsg3 depletion of desmosomes and 
acantholysis (267).
Autoantibody-Mediated Changes in Cell Signaling 
Contribute to Loss of Cell Adhesion in Pemphigus
The observations that polyclonal IgG from PV patients causes 
retraction of keratin intermediate filaments (thus contributing 
to intercellular loss of adhesion) in cultured murine wild-type 
keratinocytes and that plakoglobin (PG)-deficient mice do not 
show this reaction pointed to intracellular signaling mecha-
nisms contributing to acantholysis (269). Further research then 
demonstrated that PG is a suppressor of c-Myc expression and 
that PV autoantibodies trigger c-Myc upregulation by depletion 
of PG together with Dsg3; increased c-Myc then leads to cell 
Dermis
HSP27
Retraction of keratin 
intermediate filaments, 
acantholysis
polyclonal PV-IgG
p38
SB202190
c-Myc
p
p
clustering and 
endocytosis
SB216763
AG1478
EGFR
Depletion of Dsg3 
and plakoglobin
Steric 
hindrance
“Melting“ 
desmosome
monoclonal PV-IgG or 
Antibody fragments (F(ab`)2, scFv)
Binding to desmosomal Dsg3, 
clustering, endocytosis, 
weakened desmosomes
p38 independent pathway 
by steric hindrance
AG1478
Dsg3
Dsg1
FIGURE 8 | Autoantibody-induced loss of cell–cell adhesion in pemphigus. For explanation, please refer to the text.
16
Ludwig et al. Autoantibody-Induced Pathology
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 603
proliferation and weakened intercellular adhesion. These find-
ings were corroborated by pharmacological inhibition of c-Myc, 
resulting in an inhibition of the ability of PV autoantibodies 
to cause acantholysis in mice (270, 271). As another signaling 
cascade extensively studied in pemphigus pathophysiology is the 
p38MAPK-signaling pathway (272–274). HSP27 and p38MAPK 
have been shown to be phosphorylated upon incubation of 
human keratinocyte cell cultures with PV-IgG (272, 273) and 
to be linked to internalization of Dsg3 (275). Blister formation 
was blocked in vivo by pharmacological inhibition of p38MAPK 
and its downstream targets when studied in the passive transfer 
mouse model for PV and PF (274, 276, 277), and this signaling 
cascade was also shown to be functional in patients’ skin (278). 
Downstream of p38, epidermal growth factor receptor (EGFR) 
signaling was shown to be activated in human keratinocytes after 
addition of PV autoantibodies, and again, inhibition of EGFR 
signaling prevented blistering induced by PV-IgG in mice (118). 
What has not been fully resolved is the issue of whether p38 
activation is a primary event causing acantholysis or is secondary 
to initial loss of cell adhesion (235).
Attempting to integrate published, but sometimes seemingly 
contradictory data, recent research has pointed out that (i) steric 
hindrance and (ii) Dsg3 clustering, depletion, and signaling are 
distinct events. Monoclonal pathogenic antibodies can cause loss 
of intercellular adhesion through steric hindrance without relying 
on p38MAPK signaling, whereas polyclonal PV-IgG autoanti-
bodies cause Dsg3 clustering and endocytosis via a p38MAPK-
dependent pathway (235, 260). Recent data support these findings 
and suggested that, after induction of acantholysis and activation 
of p38MAPK signaling by polyclonal PV-IgG, effective modula-
tion of the signaling pathways involved in acantholysis may even 
outbalance direct inhibition of Dsg3 binding by PV-IgG and 
rescue cell adhesion (279), potentially by upregulating other cell 
adhesion molecules not targeted by anti-Dsg3 antibodies (e.g., 
Dsg1, Dscs, cadherins).
Emerging Treatments and Novel Therapeutic Targets 
Based on Modulation of Signaling and Cell–Cell 
Adhesion
All these cell biological studies of signaling and desmosomal 
adhesion in pemphigus have led to innovative and new appro-
aches to treatment. For example, cross-linking the adhesive 
interfaces of Dsgs by use of a specific tandem peptide successfully 
stabilized adhesion and inhibited PV-IgG-mediated activation 
of the central p38MAPK pathway and skin blistering (119). 
Overexpression of plakophilin-1, an intracellular armadillo pro-
tein that links desmosomal cadherins to keratin intermediate fila-
ments of keratinocytes, resulted in hyperadhesive desmosomes 
that were significantly less prone to PV-IgG-mediated pathology 
(280). Introducing a point mutation into DP (DP-S2849G) led 
to inhibition of both Dsg3 depletion from the cell surface and 
keratin filament retraction caused by PV-IgG (281), by prevent-
ing protein kinase C-dependent phosphorylation of DP at that 
specific site. Since the protein kinase C inhibitor Bim-X has the 
same inhibiting effects, this compound may serve as an important 
new pharmacological tool in pemphigus.
Interestingly, studying the precise mechanisms of seemingly 
“boring” but very effective corticosteroid therapy in pemphigus 
disease can yield new therapeutic insights as well. As previously 
assumed, corticosteroids do upregulate Dsg3 transcription in pri-
mary human keratinocytes. In addition, recent data point to inhi-
bition of Stat3 as a key mechanism. Similarly, inhibition of mTOR 
by rapamycin (i.e., sirolimus) is Stat3-dependent and upregulat-
ing Dsg3 transcription, explaining how PV-IgG-mediated effects 
are antagonized by rapamycin and corticosteroids (282).
Very recently, researchers in the pemphigus field have made 
an important contribution to the treatment of all autoimmune 
disease: engineered human T  cells that express a chimeric 
autoantibody receptor (CAAR), consisting of the PV autoantigen, 
desmoglein (Dsg) 3, fused to CD137–CD3z signaling domains 
were generated. These Dsg3 CAAR-T  cells showed specific 
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cytotoxicity against cells expressing anti-Dsg3 BCRs in vitro and 
expand, persist, and specifically eliminate Dsg3-specific B cells 
in vivo. Thus, CAAR-T cells may provide an effective and also 
common strategy for specific targeting of autoreactive B cells in 
antibody-mediated autoimmune disease (117).
Taken together, these data on autoantibody-mediated changes 
of cell signaling in a group of prototypic autoimmune diseases 
illustrate that studying the potentially multifaceted roles of the 
target antigens is of the utmost importance: as shown for the 
desmosomal autoantigens in pemphigus diseases, Dsgs are not 
just structural components critical for adhesion but also critical 
regulators of signal transduction, affecting differentiation, cell 
homeostasis, and carcinogenesis (283–285). Integrating all these 
and dissecting the precise mechanisms of standard therapy may 
suggest promising new targets for therapy and modulation of 
autoimmunity.
AUTOANTIBODY-INDUCED TTP:  
ANTI-ADAMTS13 ANTIBODIES
Clinical Presentation, Epidemiology, 
Treatment, and Treatment Challenges
Thrombotic thrombocytopenic purpura is a thrombotic micro-
angiopathic disorder caused by a deficiency in the multidomain 
metalloprotease ADAMTS13 (A Disintegrin And Metalloprotease 
with ThromboSpondin type 1 repeats, number 13) (286, 287) 
(Figure 9A). In the absence of ADAMTS13, ultra-large hyper-
active von Willebrand factor (VWF) multimers accumulate in 
the circulation and spontaneously bind platelets. The resulting 
VWF-rich microthrombi block capillaries and arterioles in dif-
ferent organs, thereby preventing oxygen supply (Figure  9B). 
Patients suffer from recurrent episodes of severe organ failure, 
which without urgent treatment can be fatal. Organ involvement 
is variable and can comprise multiple organs, most predomi-
nantly brain, heart, and kidney (287). TTP is clinically diagnosed 
by the occurrence of severe thrombocytopenia and hemolytic 
anemia (288, 289). It is assumed that platelets are consumed in 
the microthrombi and that red blood cells rupture as they are 
pushed through the blocked microcapillaries and arterioles 
resulting in the appearance of schistocytes, as well as increased 
levels of hemoglobin and haptoglobin. Tissue damage resulting 
from occlusive VWF-rich microthrombi furthermore results in 
increased levels of lactate dehydrogenase. TTP diagnosis is ascer-
tained by determination of ADAMTS13 activity (<10%) allowing 
differentiating TTP from other microangiopathic disorders like 
hemolytic uremic syndrome (286). Congenital TTP is caused by 
the presence of mutations in the ADAMTS13 gene and occurs in 
~5% of the TTP patients. About 95% of TTP patients suffer from 
acquired TTP. These patients develop anti-ADAMTS13 autoanti-
bodies and hence suffer from the autoimmune form of the disease 
(290). Acquired TTP with severe ADAMTS13 deficiency is an 
orphan disease with an incidence rate of around 2–6/1,000,000 
patients per year (286, 291). Since in a subset of TTP patients in 
remission, ADAMTS13 activity is still below 10%, secondary trig-
gers like pregnancy, infection, and surgery have been suggested 
to induce TTP.
Infusion with fresh frozen plasma is the treatment of choice 
for congenital TTP patients to provide sufficient levels of func-
tional ADAMTS13. Plasma exchange, where patient plasma is 
exchanged with fresh frozen plasma, is used to treat acquired TTP 
patients in order to remove anti-ADAMTS13 autoantibodies and 
to supply active ADAMTS13. To treat the underlying autoimmune 
disorder in acquired TTP, an immunosuppressive corticosteroid 
therapy is started together with the plasma exchange therapy 
(288, 289, 292). Rituximab, the anti-CD20 mAb targeting mature 
and memory B-cells, is now additionally administered to those 
acquired TTP patients experiencing a suboptimal response to 
plasma exchange and corticosteroid therapy and to patients suf-
fering from TTP relapses (293–295). Although standard therapy 
(plasma exchange and immunosuppressive therapy) reduces the 
mortality rate in 80–90% of TTP patients, mortality remains at 
10–20% (292). In addition, plasma exchange is a challenging 
therapy for TTP patients as the patients have a poor clinical 
condition and a high number of plasma exchanges is required 
with large volumes of plasma. Major complications linked with 
plasma exchange are observed and are related to systemic infec-
tion, venous catheter obstruction, hypotension, hypoxia, venous 
thrombosis, non-fatal cardiac arrest, and anaphylaxis (288).
Pathogenesis of Acquired TTP
Autoantibodies play a predominant role in the pathophysiol-
ogy of acquired TTP. Anti-ADAMTS13 autoantibodies either 
inhibit ADAMTS13 function and/or clear ADAMTS13 from the 
circulation (296). Both processes result in the absence of active 
ADAMTS13 in patient plasma leading to the accumulation of 
prothrombotic ultra-large VWF multimers and spontaneous 
VWF-rich microthrombi formation, the hallmark of acute TTP 
episodes. The presence of both, free anti-ADAMTS13 autoanti-
bodies and circulating autoantibody–antigen immune complexes, 
has been described in plasma of acquired TTP patients (297). 
Anti-ADAMTS13 autoantibodies are mainly of the IgG class, 
with IgG4 being the most prevalent, but IgM and IgA autoanti-
bodies have also been reported (298). The IgG4 subclass is also 
most predominantly observed in circulating immune complexes 
(297). Accordingly, moderately elevated complement activation 
is observed during acute TTP episodes (299–301). It is however 
unclear whether the circulating autoantibody–ADAMTS13 
immune complexes activate complement and play a role in the 
pathophysiology of TTP.
Antibody titers change during acute phases and remission. 
The autoimmune response in acquired TTP is polyclonal but 
with immunodominant epitopes in the ADAMTS13 spacer 
domain (Figure 9A) (290, 302). Plasma screening of acquired 
TTP patients against the different ADAMTS13 domains revealed 
that 90–100% of acquired TTP patients have autoantibodies with 
an epitope in the spacer domain (Figure 9A) while 30–50% of 
the patients additionally have antibodies directed against other 
ADAMTS13 domains (M, D, T, C, T2-8, and CUB1-2, Figure 9A) 
(290, 296, 302). Many anti-spacer autoantibodies have been cloned 
from acquired TTP patients and were shown to have a strong, 
weak, or absent in vitro inhibitory effect on ADAMTS13 func-
tion (296, 302–305). The ADAMTS13 spacer domain contains 
a major exosite for binding to its substrate VWF explaining why 
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FIGURE 9 | Structure of ADAMTS13 and the frequency of autoantibodies targeting specific domains and graphical representation of the 
pathophysiology of acquired thrombotic thrombocytopenic purpura (TTP). (A) ADAMTS13 consists of a metalloprotease (M; orange) and disintegrin-like (D; 
blue) domain, a thrombospondin type-1 repeat (T1; green), a cysteine-rich (C; purple) and spacer (S; pink) domain, seven additional thrombospondin type-1 repeats 
(T2–T8; green), and two CUB domains (CUB1-2; red). Epitope mapping of anti-ADAMTS13 autoantibodies revealed that most patients (90–100%) have 
autoantibodies against the cysteine-spacer domain (indicated with the largest antibody). The size of the other antibodies in this figure demonstrates the relative 
frequency of these autoantibodies in the plasma of acquired TTP patients. (B) In normal conditions, UL-VWF released from activated endothelial cells is directly 
proteolysed by ADAMTS13, preventing spontaneous platelet binding. In the pathophysiology of acquired TTP, autoantibodies inhibit ADAMTS13 activity. UL-VWF 
multimers accumulate in the circulation and spontaneously bind platelets. This process results in the formation of VWF-rich microthrombi blocking the circulation in 
microcapillaries and arterioles.
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anti-spacer domain autoantibodies can inhibit ADAMTS13 func-
tion. Non-inhibitory cloned anti-spacer antibodies are expected 
to clear ADAMTS13 from the circulation as it was demonstrated 
by Thomas et  al. that the IgG fraction isolated from acquired 
TTP patients contains non-inhibitory anti-ADAMTS13 autoan-
tibodies and that ADAMTS13 antigen levels were low in these 
patients (296). Only a few anti-ADAMTS13 autoantibodies with 
an epitope outside the spacer domain have been cloned. These 
comprise autoantibodies with an epitope in the ADAMTS13 
metalloprotease, disintegrin, and CUB domains, but their effect 
on ADAMTS13 function has not yet been studied (305, 306). 
Anti-metalloprotease autoantibodies could inhibit ADAMTS13 
function, as the metalloprotease domain harbors the active site of 
the enzyme. Anti-disintegrin or anti-CUB autoantibodies could 
have similar effects, as these domains are involved in binding 
and docking ADAMTS13 to VWF, respectively. However, in 
addition, autoantibodies could merely clear ADAMTS13 from 
the circulation. Whether deposition of circulating immune 
complexes in tissues also play a role in the pathophysiology of 
acquired TTP remains to be determined.
We showed that injection of a murine anti-metalloprotease 
mAb that potently inhibited ADAMTS13 function in  vitro 
could induce acquired TTP in baboons (307). This experiment 
shows that anti-ADAMTS13 antibodies play a central role in the 
pathophysiology of acquired TTP. Recently, it was shown that 
injection of a cloned inhibitory anti-spacer single chain (sc) Fv 
autoantibody into mice also resulted in acquired TTP when TTP 
symptoms were triggered with Shiga toxin or recombinant VWF 
(305, 308). TTP symptoms presented due to full inhibition of 
ADAMTS13 activity in both animal models, as animals injected 
with non-inhibitory control antibodies did not develop TTP 
symptoms. However, not all acquired TTP patients have strong 
inhibitory anti-spacer autoantibodies and 30–50% of the patients 
also have autoantibodies against other ADAMTS13 domains.
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Hence, animal models where individual autoantibodies or 
mixtures of these autoantibodies are injected need to be performed 
to further unravel the contribution of all these autoantibodies in 
the pathophysiology of acquired TTP. Indeed, since the immune 
response in acquired TTP is polyclonal, it is reasonable to specu-
late that multiple autoantibodies will contribute to inhibition 
and/or clearance of ADAMTS13 in 30–50% of the patients. It is 
currently less obvious to study the clearance of anti-ADAMTS13 
autoantibodies as most available cloned autoantibodies are either 
mounted on an IgG1 or IgG4 scaffold, or are scFv fragments. 
Mouse models cannot be used to perform these studies as clear-
ance mechanisms in mice are too different from those in humans.
The mechanism of autoantibody development in acquired 
TTP patients is currently not known but both environmental 
and genetic factors will probably play a role as shown in other 
immune diseases. Indeed, HLA-DRB1*11 has been shown to be 
overrepresented in patients with acquired TTP compared to con-
trols (309). The role of specific CD4+ T-cells in acquired TTP has 
only recently been investigated. It was shown that ADAMTS13 
is endocytosed by dendritic cells via the macrophage mannose 
receptor (310). Peptides derived from the carboxy-terminal CUB2 
domain of ADAMTS13 were preferentially presented, showing 
that the CUB2 domain contains potential immunodominant 
T cell epitopes (310). Investigating ADAMTS13 reactive CD4+ 
T cells from acquired TTP patients showed that CUB2 domain 
reactive CD4+ T  cells might be involved in the etiology of 
acquired TTP (311).
Emerging Treatments and Novel 
Therapeutic Targets
Recombinant (r)ADAMTS13 is currently under development as 
an alternative treatment for TTP. It is effective to treat congenital 
TTP symptoms in mice (312) and acquired TTP symptoms 
in rats, where rADAMTS13 was able to overcome circulating 
inhibitors and reconstitute ADAMTS13 activity (313). A Phase I 
clinical study is currently going on to assess rADAMTS13 in the 
treatment and prophylaxis of congenital TTP (NCT02216084). 
Apart from providing active ADAMTS13 to patients, a treatment 
has been developed that prevents the formation of VWF-rich 
microthrombi, which play a detrimental role in TTP patho-
physiology. Others and we showed that administration of an 
antibody blocking the binding between VWF and platelets results 
in the prevention and treatment of acquired TTP in preclinical 
animal models (314, 315). The inhibitory anti-VWF nanobody 
caplacizumab in combination with standard therapy was tested 
in clinical trials and induced a faster resolution of acute TTP 
episodes compared to placebo in acquired TTP patients (112). A 
second therapy that aims at preventing or reducing VWF–platelet 
interactions is the FDA approved drug N-acetylcysteine (NAC) 
currently used to treat acetaminophen overdose or to decrease 
the viscosity of mucous secretions in respiratory disorders. NAC 
reduces disulfide bonds in mucins and was shown to also reduce 
disulfide bonds in VWF multimers, thereby reducing the forma-
tion of VWF-platelet thrombi in mesenteric venules of mice 
(316). NAC has been administered to patients with refractory 
TTP but the outcome has been variable (317–320). To determine 
the clinical value of NAC, patients are currently being recruited 
(ClinicalTrials.gov: NCT1808521). Another drug that is evaluated 
to treat refractory TTP is the proteasome inhibitor bortezomib. 
Although case reports have suggested a benefit for the treatment 
of refractory TTP (73, 320), possibly by eliminating autoreactive 
plasma cells producing anti-ADAMTS13 antibodies (321), pro-
spective clinical trials are needed to investigate the effectiveness 
of this drug in the treatment of refractory TTP.
AUTOANTIBODY-INDUCED CELL LYSIS: 
IDIOPATHIC THROMBOCYTOPENIC 
PURPURA (ITP) AND AUTOIMMUNE 
HEMOLYTIC ANEMIA
Immune thrombocytopenic purpura (formerlyITP) and autoim-
mune hemolytic anemia (AIHA) are autoimmune diseases that 
are characterized by reduced levels of erythrocytes or platelets 
resulting in anemia or platelet deficiency, respectively. AIHA and 
ITP may both appear as secondary disease in consequence of a 
different medical condition or can be induced by medical treat-
ments. In contrast to these secondary forms, the pathogenesis of 
the primary diseases is not fully understood but in the majority of 
patients, autoantibodies directed against erythrocytes or platelets, 
respectively, can be detected.
Primary AIHA seems to be exclusively caused by such 
autoantibodies while in primary ITP these can only be detected 
in 60% of the patients (322). In the residual cases, a contribu-
tion of cytotoxic T cells is considered (323) but it is likely that 
autoantibody levels are simply undetectable due to the quantita-
tive binding to platelets and their subsequent fast elimination. 
The removal and destruction of erythrocytes or platelets in 
AIHA or ITP, respectively, is mainly mediated by Fcγ-receptor 
(FcγR)-based mechanisms in cases where the autoantibodies are 
of the IgG class. While the role of complement in the removal of 
platelets does not play a prominent role in ITP (324), the situa-
tion in AIHA is somewhat different. In a considerable fraction 
of patients, IgM autoantibodies are involved that efficiently can 
activate complement, which is not the case when erythrocytes are 
opsonized by IgG (325). As the different pathways of red blood 
cell destruction require also different treatments, the determina-
tion of the involved autoantibody Ig class is essential.
The contribution of FcγR-mediated effector functions to the 
pathogenesis of ITP triggered by opsonized platelets has identi-
fied an association with reduced expression levels or impaired 
signaling of inhibitory FcγRIIB (326, 327) as well as the presence 
of a functional copy of the activating FcγRIIC gene (328). Similar 
genetic association studies have been conducted for the role of 
the activating FcγRs. For the FcγRIIA H/R131 dimorphism, 
an elevated prevalence of the FcγRIIA-R131 allele, which has a 
lower affinity for IgG2 and a higher one for IgG3, was observed 
(329, 330), while for that of FcγRIIIA (F/V158) diverging results 
have been reported in ITP patients (331–333).
While the impact of activating FcγRs on both human het-
erogeneous diseases remains unclear, studies in mouse models of 
experimental AIHA and ITP could demonstrate a contribution to 
disease severity mediated by activating FcγRs, namely, FcγRIIIA 
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(329, 334–337). In a therapeutic approach, the hypothesis was 
tested if blockade of FcγRIII can improve ITP in chronic refrac-
tory patients. Using an anti-FcγRIIIA antibody, around 50% of the 
included patients responded with significantly improved platelet 
levels but treatment was accompanied by severe adverse events. 
Using several engineered versions of the anti-FcγRIII antibody, 
the authors demonstrated that the observed adverse events were 
independent of Fc-mediated effector functions or immunogenic-
ity (338) but rather depended on the dimerization of FcγRIII 
by both Fab fragments of the used antibody. This finding was 
supported by a study using a passive ITP mouse model in which 
a monovalent anti-FcγRIII antibody was used. This construct 
which blocks immune complex-mediated engagement of FcγRIII 
mediated an efficient inhibition of antibody-dependent platelet 
removal without triggering adverse events (339).
In a related approach, a soluble FcγR was used with the inten-
tion to compete with cellular FcγRs for the binding of opsonized 
platelets. As a consequence, the platelet binding to FcγRs is 
blocked and destruction and cellular activation of the immune 
cells is inhibited (340). In chronic ITP patients, the drug was well 
tolerated and induced a sustained platelet response during the 
3-month follow-up period (341). Both approaches underline the 
relevance of the FcγR system in autoimmune diseases and may 
provide new treatment options for the management of ITP, AIHA, 
and eventually other antibody-mediated autoimmune diseases.
AUTOANTIBODY-INDUCED VASCULAR 
INFLAMMATION
Antineutrophil cytoplasmic autoantibody (ANCA)-associated 
vasculitides (AAV) comprise a group of three different rare and 
potentially life-threatening chronic inflammatory vessel diseases 
of unknown etiology: granulomatosis with polyangiitis (GPA), 
microscopic polyangiitis (MPA), and eosinophilic granulomato-
sis with polyangiitis (EGPA). GPA is associated with proteinase 
3 (PR3)-specific ANCA (PR3-ANCA), whereas MPA and—less 
commonly—EGPA are associated with myeloperoxidase 
(MPO)-specific ANCA (MPO-ANCA). Usually P33 and PR3-
ANCA are detected by indirect fluorescence (see below). AAV 
predominantly affect small vessels, i.e., intraparenchymal small 
arteries, arterioles, capillaries, and venules. The vasculitis is his-
topathologically characterized by fibrinoid necrosis and paucity 
of immune complexes (“pauci-immune vasculitis”). In addition 
to systemic vasculitis, GPA displays a peculiar propensity for a 
predominantly extravascular necrotizing granulomatous inflam-
mation mainly affecting the upper and/or lower respiratory 
tract. In EGPA, extravascular eosinophilic infiltration is found 
in various tissues. In contrast, MPA displays no extravascular 
granulomatous inflammation (342–344).
In central Europe, GPA is the most common form of AAV 
(incidence 10 per million, prevalence 98 per million), followed 
by MPA (incidence 2 per million, prevalence 28 per million) 
and EGPA (incidence 1 per million, prevalence 23 per million). 
However, these numbers may underestimate the true incidence 
and prevalence of AAV due to referral bias. The mean age at 
disease manifestation lies between 50 and 70 years. Women and 
men are equally affected (345). AAV as a group are characterized 
by diversity and at the same time considerable overlap of clinical 
and pathological features. Malaise, flu-like symptoms, arthralgia, 
and myalgia often herald the onset of AAV. Respiratory tract 
manifestations are the most frequent presenting features in 
GPA. Involvement of upper and/or lower airways with rhinitis, 
sinusitis, and pulmonary infiltrates is a distinctive feature of 
GPA. Asthma, pulmonary infiltrates, and hypereosinophilia with 
eosinophilic vasculitis and inflammation affecting various organs 
are characteristic features of EGPA. Pulmonary-renal syndrome 
with alveolar hemorrhage as a result of capillaritis and rapidly 
declining renal function due to focal segmental necrotizing glo-
merulonephritis with crescent formation affects the majority of 
patients with full-blown GPA and MPA. Renal involvement is less 
common in EGPA. Owing to its systemic nature, the vasculitis 
may affect any organ in AAV. Localized forms of GPA restricted to 
the upper and/or lower respiratory tract and a renal-limited form 
of MPA are less commonly encountered (343).
Prior to the introduction of immunosuppressive therapy, 
AAV used to be an inevitably fatal condition. With the advent 
of corticosteroids and establishment of immunosuppressive cyto-
toxic treatment protocols in randomized trials, the outcome and 
survival rates have considerably improved (343, 346). However, 
the mortality ratio continues to be increased (2.6, 95% CI 2.2–3.1) 
compared with an age- and sex-matched general population 
(347). Despite further advances in treatment such as the use 
of rituximab for the induction and maintenance of remission, 
the course of AAV remains characterized by chronicity, risk of 
relapse, and complicating comorbidities. Thus, major goals of 
research are the prevention of disease through a personalized 
medical approach allowing the evaluation of predisposing genetic 
risk factors for disease manifestation and relapse, the determina-
tion of triggering environmental factors, and the development 
of combined targeted therapies intervening early in the break of 
tolerance and with mechanisms fostering chronic non-resolving 
inflammation in AAV (346).
Antineutrophil cytoplasmic autoantibodies are highly sensi-
tive and specific for AAV. Combining immunofluorescence tech-
nique and ELISA (see below) for the detection of ANCA yields a 
sensitivity of 70% and specificity of 99% for AAV (348). ANCA 
levels do not strongly reflect disease activity. Therefore, ANCAs 
cannot be used for the guidance of immunosuppressive therapy 
in clinical practice (349). However, persistence of ANCA after the 
induction of remission is strongly associated with an increased 
risk for relapse in AAV (350). ANCAs are rarely detected in 
healthy controls. Interestingly, there is no evident co-occurrence 
with other autoantibodies suggesting differences in the break of 
tolerance between different autoimmune diseases (63). ANCA 
with specificity for a subset of immunodominant epitopes are 
associated with disease activity in AAV (351). ANCAs induce 
respiratory burst and degranulation of cytokine- and complement 
factor C5a-primed neutrophils in vitro (352, 353). Prestimulation 
of neutrophils with cytokines promotes translocation of the 
target antigens of ANCA on the cellular surface. Interaction of 
ANCA with both its target antigen on the cellular membrane and 
Fcγ-receptors IIa or IIIb is required for the full activation and 
subsequent degranulation of neutrophils (354, 355). Binding of 
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ANCA to both, the membrane-bound ANCA targets MPO and 
PR3 and Fcγ-receptors IIa or IIIb, generates activation signals dis-
tinct form conventional Ig-induced activation via Fcγ-receptors 
(356). Genes of pro-inflammatory mediators are upregulated 
following stimulation with ANCA (357). ANCAs facilitate 
adhesion and transmigration of cytokine-primed neutrophils 
across the endothelial cell barrier in vitro and in vivo as observed 
in flow-chamber experiments and by intravital microscopy 
(358, 359). Transfer of MPO-ANCA generated from MPO-knockout 
mice immunized with mouse MPO induces glomerulonephritis 
and vasculitis in susceptible mice. The genetic background of the 
mouse determines the severity of glomerulonephritis in these 
models (360). The alternative complement pathway is activated 
in AAV. Complement factor C5a receptor deficiency ameliorates 
MPO-ANCA-induced experimental glomerulonephritis in mice 
(361). Owing to structural and biologic differences between 
human PR3 and its rodent homolog, the development of models 
for PR3-ANCA-induced vasculitis has remained a challenge. 
Pathogenicity of PR3-ANCA resulting in acute vascular dam-
age has been demonstrated in immunodeficient chimeric mice 
following injection of human hematopoietic stem cells and PR3-
ANCA (362). However, extravascular necrotizing granulomatous 
inflammation was not found in the respiratory tract of these mice, 
suggesting that the pathogenesis of granulomatous inflammation 
may be separate from acute systemic vasculitis and in particular 
T-cell-dependent in GPA (362, 363).
Clinical observations, the efficacy of B-cell-depleting therapy, 
and evidence from in vitro and in vivo experiments taken together 
all lend support to the concept that ANCAs are pathogenic and 
induce a necrotizing small-vessel vasculitis. However, unresolved 
questions concern the cascade of events leading to the induction 
of pathogenic ANCA and the pathogenesis of extravascular 
granulomatosis in GPA and EGPA. Thus, key elements of the 
pathogenesis of AAV and its characteristic immune pathology 
remains to be elucidated (346). While the uptake of apoptotic 
cells and debris, a process known as efferocytosis, is usually 
immunologically silent in healthy individuals, upregulation of 
PR3 on the cell surface of apoptotic neutrophils interferes with 
normal efferocytosis in GPA. Increased PR3 expression on apop-
totic neutrophils induces the secretion of inflammatory cytokines 
including granulocyte-colony stimulating factor (G-CSF) by 
macrophages in  vitro and in  vivo. In turn, G-CSF upregulates 
PR3 expression on maturing neutrophils from GPA patients 
in the bone marrow. Thus, a G-CSF-driven autoamplificatory 
loop sustains non-resolving inflammation in GPA. Moreover, 
PR3-expressiong apoptotic cells skew the cytokine response of 
plasamocytoid dendritic cells toward the generation of Th2 and 
Th9 cytokines. In the presence of PR3-ANCA, the cytokine 
response was further skewed toward a Th17 response in a murine 
model. Accordingly, skewing of the cytokines response with an 
increase in circulating Th2, Th9, and Th17 cells was also detected 
in GPA patients (364). Notably, ectopic lymphoid structures and 
plasma cells displaying signs of autoreactivity are found in granu-
lomatous inflammation rich in neutrophils in GPA (365). Once 
tolerance is broken and pathological autoreactivity toward PR3 
and MPO established in AAV, the autoreactive immune response 
is further self-amplified by neutrophil extracellular traps (NETs). 
NETs are released by ANCA-stimulated neutrophils and contain 
the targeted autoantigens PR3 and MPO (366).
Taken together, the abovementioned studies suggest an immu-
nological paradox in which cell death, i.e., necrosis, is not only 
the endpoint of ANCA-induced neutrophil degranulation and 
inflammation in AAV but also at the same time represents the 
starting point of a cascade of pathophysiological events leading 
to chronic non-resolving extravascular and vascular inflamma-
tion and the breakdown in self-tolerance. This paradox, however, 
could explain why neutrophil-derived antigens become the target 
of pathological autoreactivity and inflammation is sustained and 
does not resolve in AAV. The cascade may initially be triggered by 
environmental factors, e.g., infections, in genetically susceptible 
persons. G-CSF and/or IL-17 could become new therapeutic 
targets for the treatment of AAV. It is inferred that targeting 
G-CSF and IL-17 interferes with fundamental pathophysiologic 
mechanisms driving non-resolving chronic inflammation and 
the break of tolerance in AAV.
AUTOANTIBODY-INDUCED 
INFLAMMATION
Autoantibody-Induced Cutaneous 
Inflammation: Pemphigoid Diseases (PD)
Pemphigoid diseases are characterized and caused by autoan-
tibodies against distinct structural components of the dermal– 
epidermal junction. Junction proteins link the cytoskeleton of 
the basal keratinocytes to the extracellular matrix of the dermis. 
Binding of PD autoantibodies leads to the separation of the epi-
dermis and dermis by a complex, yet relatively well-understood 
process. PDs comprise eight distinct disorders for which the 
molecular target antigens have been identified (367). Of these, 
due to the availability of well-defined animal models, bullous 
pemphigoid [BP, autoimmunity against type XVII collagen 
(COL17, BP180)] and epidermolysis bullosa acquisita [EBA, 
autoimmunity against type VII collagen (COL7)] are particular-
ity well studied (368–371). We here will focus on EBA because the 
expression of COL7 beyond the skin, i.e., in the gastrointestinal 
tract (372, 373), leads to a severe and difficult-to-treat clinical 
presentation. The cutaneous manifestations in EBA are hetero-
geneous: two major clinical subtypes have been described. The 
mechanobullous (non-inflammatory, classical) variant of EBA is 
characterized by skin fragility, tense blisters, scaring, and milia 
formation preferably localized to trauma-prone sites. The inflam-
matory variant mimics other PDs, and widespread vesiculobul-
lous eruptions are present. Independent of the clinical variation, 
extracutaneous manifestations are frequently observed. These 
include ocular, oral mucosa, esophagus, anal, vaginal, tracheal, 
and laryngeal lesions, which can lead to blindness, esophageal 
strictures, hoarseness, impaired phonation, and may led to 
irreversible respiratory distress (374). Overall, EBA is notori-
ously difficult to treat, and often long-term use of high doses of 
corticosteroids in combination with other immunosuppressants 
is required to achieve clinical remission (375, 376). Thus, there 
is a high, and so far unmet medical need, for the development of 
novel treatment strategies for patients with EBA.
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FIGURE 10 | Pathogenesis of inflammation and blistering in the pemphigoid disease epidermolysis bullosa acquisita. Details are explained in the text, 
where the numbering corresponds to the labeling used here.
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One of the breakthrough discoveries in EBA was the identifi-
cation of COL7 as the autoantigens in the late 1980 (377). Based 
on this insight, the pathogenic relevance of COL7 autoantibodies 
has been demonstrated (i) in vitro by demonstrating digestion of 
the dermal–epidermal junction in skin specimen incubated with 
anti-COL7 IgG or IgA and neutrophils (378, 379), (ii) in vivo by 
induction of inflammation and blistering in mice by transfer of 
anti-COL7 IgG (380, 381) or by immunization (382, 383), and 
(iii) clinically by the observation of a correlation of circulating 
autoantibody titers with clinical disease severity (384, 385). 
Subsequently, use of these animal models has greatly contributed 
to our current understanding of EBA pathogenesis. The patho-
genesis of blistering and inflammation in EBA can be divided in 
the following steps (Figure 10).
(1) The pathology-triggering event in EBA is without doubt the 
binding of the autoantibodies directed against COL7.
(2) This binding triggers the generation and/or the release of 
pro- and anti-inflammatory mediators, such as cytokines and 
complement. Of these, C5a, GM-CSF, CXCL1/2, TNF, and 
leukotriene B4 promote inflammation (44, 380, 386–389), 
while IL-1ra and IL-6 have profound anti-inflammatory 
activities (390, 391). These insights have almost exclusively 
been obtained from EBA mouse models, where inhibition of 
C5a, GM-CSF, CXCL1/2, or TNF impaired disease induction 
and/or ameliorated or even improved already manifest EBA. 
Conversely, blockade of IL-6 led to a deteriorating clinical 
EBA phenotype, while treatment with recombinant IL-6 
or anakinra had beneficial effects (371). So far, no data on 
the source of these mediators have been published. Recent 
data, however, suggest that the diversity of the cutaneous 
microbiome has a significant impact on the expression of 
inflammatory mediators in the skin (392): in immuni-
zation-induced experimental EBA, the clinical outcome, 
i.e., development of clinically manifest disease, was associ-
ated with the diversity of the cutaneous microbiome. Mice 
with a relatively low diversity of cutaneous microbiota 
developed clinical EBA, while mice with a relatively high 
diversity were protected from disease induction. Of note, 
low diversity of cutaneous microbiota was also associated 
with higher cutaneous expression of TNF and CXCL1, as 
well as CD11c. This indicates that skin-resident cells or 
keratinocytes may be a source of these cytokines known to 
modulate blistering and inflammation in EBA. In addition, 
excess production of IL-10, i.e., induced by polyclonal B cell 
activation, has been shown do directly dampen C5a-driven 
inflammatory responses in EBA (56).
(3) Overall, this mediator release prompts a vascular response, 
characterized by an increased expression of endothelial 
adhesion molecules in cutaneous vessels (393), which allows 
the CD18-dependent extravasation of Gr-1+ myeloid cells 
into the skin (394).
(4) Within the skin, myeloid cells attach to the skin-bound 
immune complexes via specific Fc gamma receptors (395, 396). 
Regarding the activating Fc gamma receptors, the Fc gamma 
receptors IIA and IIIB mediate blistering in man, and the 
Fc gamma receptor IV in the mouse. At least in the mouse, 
the inhibitory Fc gamma receptor IIB has protective effects. 
These findings identified activating Fc gamma receptors as 
a potential drug target in EBA and other PDs. Indeed, if 
the binding of activating Fc gamma receptors to the skin-
bound immune complexes is blocked, i.e., by removal of the 
sugar residues as Asn297 (397, 398), or by treatment with 
recombinant CD32-Fc (399), the induction of blistering can 
be prevented or even improved in mice with experimental 
EBA. Furthermore, the inhibitory Fc gamma receptor IIB is 
required to mediate the protective effect of high doses IgG in 
this model (400, 401).
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(5) The Fc gamma receptor-mediated engagement of the myeloid 
effector cells to the tissue-bound immune complexes triggers 
a signaling process that initially triggers Syk and Src family 
kinases (115, 402). Downstream signaling involves PI3K beta 
(403), PDE4 (120), as well as RORα (391). These insights into 
the pathogenesis of EBA have led to the identification of sev-
eral novel therapeutic targets for the treatment of the disease. 
For example, pharmacological inhibition of all of the above 
pathways hinders disease induction, and in some cases even 
improves already established disease when therapeutically 
applied.
(6) Ultimately, this process leads to the release of ROS via activa-
tion of the NADPH oxidase (394) and proteases (404), which 
cause blistering. For example, mice deficient for NCF1, a 
subunit of the neutrophil NADPH oxidase, are completely 
protected from induction of antibody transfer-induced EBA 
(394). Regarding proteases, blockade of neutrophil elastase 
or gelaninase B almost completely abolished dermal–epi-
dermal separation of cryosections of skin incubated with 
EBA patient sera and leukocytes (404). In line, neutrophil 
elastase deficient mice are completely protected from blister 
induction by transfer of anti-type XVII collagen antibodies 
(405). Recent data also suggest that T  cells can modulate 
this myeloid-driven inflammation. More specifically, γδ and 
NK-T cells promote inflammation and blistering by enhanc-
ing the migratory capabilities of myeloid cells (406).
(7) Quite recently, the actin remodeling protein Flightless I 
(Flii), known to be involved in would healing (407), has 
been identified as a potential therapeutic target for the 
treatment of EBA. In accordance to observations in would 
healing, overexpression of Flii led to a more severe clinical 
phenotype in antibody transfer-induced EBA (408), while 
pharmacological inhibition had therapeutic effects in mice 
with EBA (409). These findings indicate that processes con-
trolling would healing are important to resolve inflammation 
and blistering, opening new avenues in our understanding 
of EBA pathogenesis, as well as pointing to so far neglected 
potential therapeutic targets.
Based on this detailed understanding of autoantibody-induced 
pathology in PD, several therapeutic targets have emerged. In 
my personal opinion, topical treatment using small molecules 
inhibiting signal transduction will have a significant impact on 
the management on patient care.
Autoantibody-Induced Carditis
Myocarditis, defined as an inflammation of the myocardium, 
is a major cause of heart failure in young adults. Furthermore, 
myocarditis can lead to dilated cardiomyopathy (DCM), being 
the most frequent cause for heart transplantation (410). DCM is 
characterized by progressive depression of myocardial contrac-
tile function and ventricular dilation. Clinical manifestation of 
myocarditis ranges from patients without any relevant symptoms 
to acute cardiogenic shock. Most patients display flu-like symp-
toms, palpitations, or arrhythmias. Myocarditis is diagnosed by 
histological examination of endomyocardial biopsies (EMB). 
In echocardiography, CT and MRI an impaired wall movement 
and reduced ejection fraction might be observed. Changes in 
electrocardiogram can include ST elevation, heart block, and 
low voltage. Elevated levels of troponin T (TnT) and troponin 
I (TnI) suggest unspecific myocyte damage (410–412). Apart 
from infectious agents, like virus or bacteria, myocarditis can 
be caused by autoimmune reactions. Such an autoimmune myo-
carditis is characterized as histological confirmed myocarditis 
with no detectable viral genome in EMB (413) and detection of 
autoantibodies.
The induction of an autoimmune response against the heart 
can be a consequence of cardiac injury induced by endogenous or 
exogenous factors (Figure 11). Triggering agents could be acute 
infections and toxic or ischemic events resulting in presentation 
of potentially antigenic determinants to the immune systems. 
Furthermore, molecular mimicry and cross-reactivity may play 
an important role. The resulting autoimmune reaction could lead 
to perpetuation of immune-mediated cardiac damage involving 
either cellular (e.g., T-cell), and/or humoral (e.g., B-cell) immune 
responses. Co-activation of both the innate and the adaptive 
immune system is possible (414). Thus, autoantibodies could be 
observed in all forms of inflammatory cardiomyopathies (415). 
These autoantibodies are targeted against various self-antigens, 
some of which are specific for heart cells. Already in 1987, Neu 
and colleagues demonstrated the presence of heart-specific 
autoantibodies following murine Coxsackievirus B3 myocarditis 
(416). Furthermore, it has been reported that heart-reactive anti-
bodies were present in 59% of patients with myocarditis when 
rat tissue was used as substrate, whereas 20% of patients with 
DCM and less than 5% of healthy controls displayed antibodies 
against rat heart tissue (417). A study by Caforio et al. showed 
a higher frequency of circulating autoantibodies in relatives 
of DCM patients, which might be a possible predisposition to 
develop DCM (418). Another possible genetic predisposition 
for developing an autoimmune myocarditis could be observed 
in animal models. Here, mice of different genetic background 
showed variation in susceptibility to develop an inflammation 
of the myocardium after viral infection or immunization with 
heart-specific autoantigenes (419, 420).
Negative inotropic effects can cause impairment of cardiac 
function through autoantibodies. Moreover, apoptosis of car-
diomyocytes and activation of the complement system may play 
a role (414). In fact, autoantibodies against adenine-nucleotide 
translocase induce functional consequences, which could be 
shown in vitro (421).
The “Etiology, Titre-Course, and Survival Study” investigates 
the prevalence and kinetics of autoantibodies in different forms of 
heart failure in a large multicenter trial (422). Moreover, various 
studies have investigated the treatment of autoimmune myocar-
ditis beyond regular heart failure medication. The use of anti-
inflammatory drugs like Igs, corticosteroids, azathioprine, and 
cyclosporine is one therapeutic approach (423, 424). However, 
for an immunosuppressive therapy, patients have to be virus-
negative, because patients with biopsy-based exclusion of virus 
respond much better to the therapy (425, 426). Another approach 
is the treatment with IVIG. Here, an improved recovery of left 
ventricular function with a better survival tendency during the 
first year could be observed (427). The mode of action of IVIG 
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FIGURE 11 | Potential pathomechanisms in autoantibody-induced carditis and therapeutic options. Release of self-antigens through cardiomyocte 
damage caused by exogenous or endogenous factors can induce an autoimmune response against myocardial tissue in genetic predisposed patients leading to 
secondary myocardial damage. Therapeutic options could be immunoadsorption, treatment with intravenous immunoglobulin (IVIG) and/or immunosuppressive 
medication.
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preparation may be based on the binding and neutralization of 
circulating autoantibodies (428). In addition to IVIG therapy, 
immunoadsorption (IA) can be also used to eliminate cardiotoxic 
antibodies in the patient’s plasma. Here, the antibodies bind to a 
column adsorbing IgG with higher affinity than IgA and IgM. At 
least 18 h after the last IA treatment, patients receive polyclonal 
IgG infusion to restore their IgG levels. Due to IA, functionally 
active cardiac autoantibodies are removed resulting in improved 
hemodynamic parameters and biopsy-proven decrease in 
lymphocytic infiltration and expression of cellular adhesion mol-
ecules (423). According to this, a study by Wallukat et al. showed 
that IA removed circulating IgG3 antibodies targeting β1-AR. 
The clearance of these antibodies led to an improvement of heart 
function and a shift to a lower NYHA state (429).
Despite various research approaches, the pathogenesis of 
autoimmune myocarditis is yet not fully understood. A better 
understanding of the mechanisms leading to an autoimmune 
response against cardiac antigens may contribute to a more spe-
cific therapy. To investigate the role of autoantibodies and their 
influence on disease progression, different mouse models, e.g., 
immunization with cardiac peptides derived from TnI or myosin, 
have been established (430).
Taken together, different studies demonstrate an association 
between autoimmune damage related to cardiovascular disorders 
and the generation of functional antibodies against various pro-
teins. Some therapeutic approaches reached clinical relevance but 
further studies are needed to confirm their benefit.
Autoantibody-Induced Joint  
Inflammation: RA
With an estimated incidence of 0.6–1%, RA represents a major 
challenge for an aging Western population (431). Despite the 
availability of highly efficient therapies, such as the blockade 
of pro-inflammatory cytokines, B  cell depletion, or a more 
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generalized immunosuppression, many patients do not respond 
to therapy or become refractory to treatment. Thus, an in-depth 
understanding of the underlying mechanisms causing joint 
inflammation and bone destruction may be critical to identify 
novel therapeutic avenues. Although the final proof of an essential 
role of autoantibodies in the disease pathology of RA in humans 
is lacking, the strong association of autoantibodies recognizing 
cyclic citrullinated proteins (CCP-specific antibodies), which 
were shown to directly impact osteoclast activity, or the presence 
of rheumatoid factor antibodies, makes this scenario highly likely 
(431). Moreover, certain activating FcγR alleles were shown to 
be associated with the incidence or severity of disease, providing 
further indirect evidence for a contribution of autoantibodies 
to disease pathology (432). The strongest evidence for a critical 
role of the humoral immune system in RA stems from preclinical 
model systems, which have permitted studying the complex dis-
ease mechanisms involved in the molecular and cellular processes 
ultimately resulting in joint inflammation and bone destruction 
(433). In these studies, the passive transfer of serum from mice 
with inflammatory arthritis into healthy animals was sufficient 
for induction of joint inflammation and bone destruction.
Using a range of knockout mouse strains deficient in Fcγ-
receptors or components of the complement pathway has helped 
to elucidate critical mechanisms responsible for triggering 
inflammation. Of note, both the complement pathway and 
cellu lar Fc-receptors were shown to participate in autoantibody-
dependent inflammation and bone destruction (434). With 
respect to the involvement of complement, not the classical 
antibody-dependent pathway but rather non-classical pathways 
were shown to be essential for tissue inflammation, quite similar 
to what was observed for autoantibody-mediated skin blistering 
diseases (434). With respect to Fc-receptors, a hierarchy of the 
involvement of different receptors and cell types has emerged 
(Figure  12). Immediately after autoantibody injection, a mast 
cell-dependent opening of the vasculature was observed, which 
was abrogated in FcγR but not in complement-deficient animals 
(435, 436). Similar to the human disease, IL-1β, IL-6, and TNFα 
were suggested to be crucial for initiation and maintenance of 
inflammation (437). Interestingly, IL-1 secreted by mast cells was 
suggested as a key for initiation of inflammation (438). Apart 
from mast cells, tissue-resident macrophages were also suggested 
to be a key component during the very early phase of inflam-
mation (439). Establishment and maintenance of inflammation 
is driven by neutrophils via activating Fc-receptors through 
activated complement components C3a and C5a (Figure  9). 
More recently, several studies have documented a critical role 
for Fc-receptors in the process of bone destruction (440–443). 
Consistent with the essential role of neutrophils and activating 
FcγRs in disease pathology, Syk or PLCg-deficient mice or ani-
mals with a neutrophil-specific deletion of Syk were protected 
from arthritis development (444, 445).
During chronic joint inflammation, osteoclasts differentiation 
from monocyte precursor cells recruited to the joint is favored by 
the pro-inflammatory milieu, which is the key event ultimately 
resulting in excessive bone resorption. It was demonstrated that 
especially inflammatory monocytes, which are recruited via the 
chemokine CCR2, differentiate into osteoclasts and are responsible 
for bone destruction (441). Moreover, autoantibodies modulated 
this process by binding to activating FcγRs expressed on immature 
and mature osteoclasts. Demonstrating the therapeutic potential 
of this approach, depletion of inflammatory monocytes or block-
ing autoantibody binding to osteoclast FcγRs diminished bone 
destruction (441). Moreover, characteristic changes in (auto)
antibody glycosylation have been noted in mice and humans with 
arthritis (446, 447). Especially pro-inflammatory IgG glycoforms 
with low levels of terminal sialic acid and galactose residues, 
which interact efficiently with activating FcγRs were shown to 
dominate during active disease. More recent studies suggest 
that not only the enhanced triggering of pro-inflammatory 
effector functions but also the lack of anti-inflammatory sialic 
acid rich IgG glycovariants may contribute to the induction of 
excessive inflammation (448). Thus, infusion of IVIGs pooled 
from thousands of donors (IVIG therapy) was shown to induce 
resolution of inflammatory arthritis and of other autoantibody-
dependent autoimmune diseases by restoring highly sialylated 
IgG glycovariants (400). As at least one part of the mechanism, 
an upregulation of the inhibitory FcγRIIb on joint infiltrating 
innate immune effector cells was shown which would increase the 
threshold for cell activation via autoantibody immune complexes 
(449). Ultimately this would reduce the downstream recruitment 
of neutrophils and osteoclast precursor cells from the blood and 
result in resolution of inflammation (448).
Taken together, activating FcγRs and activated complement 
components have been demonstrated to be of critical importance 
during all phases of autoantibody-dependent joint inflam-
mation and may therefore represent promising therapeutic 
targets. Potential strategies may include blocking autoantibody 
interaction with activating FcγRs or inhibiting their downstream 
activating signals via small molecules. Alternatively, lowering 
autoantibody half-life by blocking antibody access to the neonatal 
Fc-receptor (FcRn) may also help to reduce inflammation and 
tissue destruction (450). In addition, a more in depth under-
standing of pathways essential for initiating resolution of inflam-
mation (as induced by IVIG for example) may identify further 
treatment options to stop autoantibody pathology (448). As a 
most straightforward approach, IVIG variants with enhanced 
levels of anti-inflammatory IgG glycovariants may help to obtain 
enhanced therapeutic activity (451).
Autoantibody-Induced Inflammation  
of the Optic Nerve and Spinal Cord: 
Neuromyelitis Optica Spectrum  
Disorder (NMOSD)
NMOSD: Epidemiology, Clinical Presentation,  
and Treatment Challenges
There is a rare neurological disorder caused by autoantibodies 
directed against a membrane protein expressed on astrocytes. The 
disease, NMO, recently renamed NMOSD, is an inflammatory 
demyelinating disease of the central nervous system that primar-
ily affects optic nerves and spinal cord, and to a lesser extent brain 
(452, 453). The major clinical manifestations of NMOSD include 
recurrent bouts of eye and back pain with visual and motor 
impairment that can lead to blindness, paralysis, and death. Some 
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26
Ludwig et al. Autoantibody-Induced Pathology
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 603
patients with brain involvement manifest intractable vomiting, 
hiccups, and other symptoms. The prevalence of NMOSD is 
~1–8 per 100,000 individuals, with a female:male ratio ~8:1 and a 
median age of presentation of 30–40 years, though the disease can 
present in the children and the elderly (454, 455). NMOSD was 
originally thought to be a subtype of multiple sclerosis, another 
inflammatory demyelinating disease of the central nervous sys-
tem, but it is now clear that the diseases have distinct clinical signs 
and symptoms, pathogenesis, and responses to therapeutics. The 
mainstay of NMOSD therapy includes immunosuppression, 
plasma exchange, and B-cell depletion therapy, though new 
therapeutics are in the pipeline as discussed below. The current 
therapies are reasonably good, particularly B-cell depletion with 
rituximab, though many patients continue to have exacerbations 
and neurological deficit even with multiple drugs, and immuno-
suppressants can have significant side effects with long-term use.
NMOSD Pathogenesis
The major breakthrough in NMOSD was the discovery that 
the majority of patients have a circulating IgG1 autoantibody 
directed against AQP4, a water channel expressed at the plasma 
membrane of astrocytes throughout the central nervous system, 
including spinal cord, optic nerve, and brain (456). AQP4 is 
also expressed in various peripheral tissues including stomach, 
kidney, airways, and skeletal muscle. AQP4 functions a bidirec-
tional water channel that facilitates water movement across cell 
plasma membranes in response to osmotic gradients produced 
by solute transport. Phenotype studies in AQP4 knockout mice 
have demonstrated its involvement in brain water movement, 
neuroexcitatory phenomena, and astrocyte migration (457). 
For example, mice lacking AQP4 are partially protected from 
cytotoxic (cell swelling) brain edema in stroke and other brain 
injuries (458). While most NMOSD patients are seropositive for 
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anti-AQP4 autoantibodies (called AQP4-IgG), a small subset of 
patients are seropositive for anti-MOG (myelin oligodendrocyte 
glycoprotein) antibodies, and other patients show no detectable 
antibodies against AQP4 or MOG, though it is recognized that 
assay sensitivity remains imperfect and antibody titers vary over 
time.
The major pathological features of NMOSD lesions include 
astrocyte damage with loss of AQP4 and glial fibrillary acidic pro-
tein, inflammation with prominent granulocyte and macrophage 
infiltration, vasculocentric deposition of activated complement, 
and demyelination; in later stages, there is neuronal loss and 
scarring. The NMOSD pathogenesis mechanism in AQP4-IgG 
seropositive patients does not involve antibody effects on AQP4 
function, but rather primary damage to astrocytes by comple-
ment- and cell-mediated mechanisms, as shown in Figure 13. 
Evidence from human pathological specimens and rodent mod-
els of passive AQP4-IgG transfer suggests that binding of AQP4-
IgG to AQP4 on astrocytes initiates complement-dependent 
cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity 
(ADCC), astrocyte damage, inflammation, and BBB disrup-
tion, which leads to oligodendrocyte injury and demyelination 
(452, 453). Complement activation plays a central role in 
NMOSD pathology, both by formation of a terminal attack com-
plex on astrocytes, as well as by elaboration of anaphylatoxins 
that attract and activate inflammatory leukocytes. There may 
also be involvement of AQP4-sensitized T-cells (459), though 
it is not clear whether T-cells are involved in permeabilization 
of the BBB and/or in astrocyte cytotoxicity (460). Major, largely 
unanswered, questions in NMOSD pathogenesis include why 
disease is localized mainly to spinal cord and optic nerve without 
involvement of peripheral, tissues expressing AQP4, how early 
oligodendrocyte damage is caused by AQP4-IgG binding on 
astrocytes, and how peripherally generated AQP4-IgG enters the 
central nervous system to initiate disease.
Emerging Treatments and Novel Therapeutic Targets
Several NMOSD therapeutics in the development pipeline, 
many of which emerged from the improved understanding of 
pathogenesis (461, 462). Given the central role of complement, 
the C5 inhibitor Eculizumab is in clinical trials following encour-
aging data in a small open-label study in AQP4-IgG seropositive 
patients having frequent disease exacerbations (113). Anti-IL6 
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receptor antagonists that target antibody-producing plasma cells 
are in clinical studies. The repurposing of other approved drugs 
for NMOSD is under evaluation, including antibodies targeting 
VEGF and CD-19/20, small molecule drugs targeting neutrophils 
and eosinophils, and IVIG. Therapeutics in preclinical develop-
ment include antibodies (aquaporumab) targeting AQP4-IgG 
binding to AQP4 (463), and AQP4-IgG inactivation by enzymatic 
deglycosylation (464). Other potential targets for NMO therapeu-
tics include AQP4 cell surface expression and its supramolecular 
aggregation, complement inhibitor protein CD59, and various 
components of the CDC, ADCC, and inflammation pathways. 
Recently, experimental animal data support the possibility of a 
remyelination approach in NMOSD to limit neuron loss (465). 
Lastly, the possibility of antigen-specific tolerization against 
AQP4 is a theoretical possibility, as is autologous hematopoietic 
stem cell transplantation.
DIAGNOSTIC TOOLS FOR DETECTION  
OF AUTOANTIBODIES
Indirect Immunofluorescence
One of the “gold standards” for autoantibody determination 
maintains to be the indirect immunofluorescence assay (IFA) 
using cryosections of mammalian tissue or cultured cell lines, 
e.g., HEp-2, which is the standard substrate for the screening 
of antinuclear antibodies (Figure 14). The immunoassay prin-
ciple essentially consists of two steps: in the initial incubation 
a human sample like blood or CSF is brought into contact with 
the substrate. Subsequently, unbound sample constituents are 
washed off and the bound antibodies are visualized with 
fluorochrome-labeled secondary antibodies. The evaluation is 
done by fluorescence microscopy leading to the interpretation of 
the staining patterns. The approach has three main advantages: 
(i) all autoantigens in a given substrate are present and displayed 
in their native environment, (ii) it is possible to screen for anti-
bodies against unidentified autoantigens based on characteristic 
staining patterns such that even de novo screenings of patient 
cohorts are possible, and (iii) a negative outcome rules out the 
presence of multiple autoantibody specificities with a single 
analysis. The concentration of the respective autoantibody can 
be estimated by titering-out the sample. However, in some cases 
of autoantibodies against soluble antigens or against those that 
are prone to denaturation by necessary fixation steps, the use 
of IFA is limited. Lately, the introduction of automated digi-
talization together with the computer-assisted evaluation of the 
results (466–468) and the development of genetically modified 
cells expressing the necessary autoantigens—often designated as 
CBA—have rejuvenated the use of IFA (456, 469–475). Another 
support for the use of IFA as a routine diagnostic platform is the 
availability of incubation automates that decrease hands-on time 
and lower the total costs per analysis.
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Immunoprecipitation
Due to the highly sensitive detection of radioactive substances, 
radioimmunoassays (RIAs) based on specifically labeled anti-
gens were developed decades ago and are still a good option 
for the detection of autoantibodies against membrane proteins. 
Commonly, a radiolabel like 125-iodine is chemically or enzy-
matically attached to a purified ligand, e.g., 125-I-α-bungarotoxin 
for the labeling of AChR (476). The ligand is then incubated 
with tissue or cell extracts containing the desired membrane 
protein in a conformation that is able to specifically bind the 
ligand. Alternatively, in  vitro-translated 35-S-methionine 
labeled antigens can be used with the general limitation to simple 
(intracellular) antigens (477). The radiolabeled antigen is then 
brought into contact with a human sample and the immune 
complexes formed in this step as well as free Igs are precipitated 
by a secondary antibody or an affinity matrix like agarose-
bound staphylococcal protein G. The amount of precipitated 
radioactivity is a quantitative measure of the antibody against the 
labeled target antigen in the sample. Classically, RIAs have been 
used for the sensitive detection of autoantibodies against both 
intracellular and surface-exposed target antigens, e.g., against 
double-stranded DNA in SLE or the nicotinic AChR in MG. As 
an alternative to the radiolabel, fluorophores can be introduced 
to the target antigen, either by chemical labeling of the isolated 
target antigen or by its recombinant expression in frame with a 
fluorescent fusion protein, e.g., a variant of the green fluorescent 
protein (478).
ELISA, Fluorescence Immunoassay (FIA), 
Chemilumenescence Immunoassay 
(CLIA), and Bead-Based Assays
Another classical method for the semiquantitative determina-
tion of autoantibodies is the ELISA. Basically, a target antigen 
isolated from a native biosource or a recombinant host by a 
combination of biochemical procedures is initially immobilized 
on a solid phase, e.g., in cavities of plastic microplates or on the 
surface of membranes. The immobilization allows for sophis-
ticated blocking, washing, and stabilization steps. The sample 
to be investigated is eventually brought into contact with the 
target antigen, unbound sample constituents are removed by 
washing and bound antibodies are detected with the help of a 
secondary antibody coupled to a reporter. Microplate ELISA 
typically makes use of reporting enzymes that convert a color-
less reagent to a chromophore that is subsequently quantified 
with a spectrophotometer. Membrane-based ELISA (com-
monly designated “lineblot” or “dot blot”) instead commonly 
employ a precipitating chromophore that can be quantified by 
densitometric analysis of electronic images produced with the 
help of a flatbed scanner or a camera system (479). Alternative 
protocols are based on reagents that produce a chemilu-
menscent reaction upon conversion by the reporter enzyme 
in a CLIA or make use of a fluorophore-reporter in FIA, in 
some cases combined with fluorescent beads in the form of 
addressable laser-bead immunoassays (ALBIA) (480, 481). 
Alternatively, paramagnetic microparticles were developed as 
an additional solid phase that allows for magnetic separation 
of the target antigen from other reagents in subsequent steps. 
This bead-based assay platform is in most cases combined 
with chemilumenescence detection (482). All of the different 
methods and platforms can be partnered with sophisticated 
incubation, handling and detection devices or are integrated 
into commercially available test systems that allow for semi- 
or fully automated incubation and evaluation of the samples 
resulting in comprehensive output.
Western Blot
A further classical method for qualitative autoantibody determi-
nation is the Western blot (482). For this method, tissue or cell 
extracts containing one or several target antigens are separated by 
gel electrophoresis and subsequently transferred to membranes. 
The sample that is to be investigated for antibodies is then incu-
bated and bound antibodies are visualized with the help of a sec-
ondary antibody coupled to a reporter, e.g., an enzyme converting 
a colorless reagent to a precipitating chromophore. Generally, the 
denaturing effect of the electrophoresis limits the determination 
of antibodies to those binding denaturation-insensitive structures 
(“linear epitopes”).
Multiplexing
In most cases, screening and confirmation assays are combined 
for autoantibody determination to achieve a meaningful result 
with regard to the clinical problem. Modern test systems combine 
both approaches in one. Slides that carry more than one substrate 
per incubation field enable multiplexed testing in the IFA format. 
For example, the combination of different tissues like rat kidney, 
liver, and stomach—as commonly employed for the determination 
of antibodies associated with autoimmune liver diseases—allows 
for a more differentiated, highly specific evaluation with just one 
analysis. The biochip format made of mosaics (471, 483–485) 
of millimeter-sized glass chips coated with the diagnostically 
relevant antigenic substrates even allows the combined use of 
tissue cryosections, cultured (genetically modified and unmodi-
fied control) cells, and directly immobilized purified antigens 
for a comprehensive analysis covering the whole spectrum of 
autoantibodies relevant for differential diagnostics of autoim-
mune syndromes. Moreover, microplate and membrane-based 
ELISA as well as ALBIA can be used to form antigen profiles for 
the detection of multiple antibodies in parallel. Multiparametric 
lineblots have been developed for this purpose carrying more 
than 20 individually optimized membrane chips on a plastic 
layer and harboring antigen mixtures, individual antigens and 
even lipids (486–488).
It should be emphasized that none of the above approaches 
were used to discover TSHR autoantibodies nor can they be 
used clinically to measure TSHR antibodies in Graves’ patients. 
In 1956, using guinea pigs as a read-out, Graves sera were found 
to contain a thyroid-stimulating factor with a duration of action 
more prolonged than TSH [“long-acting thyroid stimulator” 
(LATS)] (489). LATS was later found to be an IgG molecule. 
After the discovery of the TSHR, it was shown that LATS (like 
TSH) activated thyrocyte adenylyl cyclase and competed for 
TSH binding to the TSHR. This background to TSHR antibodies 
suggests that, like Graves’ patients, some patients described as 
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seronegative for a particular autoantibody may have functional 
antibodies not detectable by the conventional approaches listed 
above.
CONCLUSION
As highlighted herein, autoantibodies may cause pathology 
thr ough a wide range of mechanisms. Insights into these pathways 
identified several novel therapeutic targets, such as FcγR-induced 
neutrophil activation, which go beyond unspecific immunosup-
pression and are already in clinical trials (340). Preclinical 
models even point toward the possibility to specifically target 
autoantibody-specific B cells and/or plasma cells, which could be 
considered as curative treatment (117). Based on the vast amount 
of insights into pathomechanism of autoantibody-induced 
pathology, some of which have been reviewed herein, we expect 
that these concepts will be evaluated in clinical trials, which will 
significantly improve the still not satisfying therapeutic options 
currently used to treat autoimmunity.
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